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Abstract
Lipocalin-2 (LCN2) is a new adipocytokine consisting of 198 amino acids. It
is also referred to as neutrophil gelatinase-associated lipocalin, siderocalin, uterocalin,
α1-microglobulin related protein, or 24p3. LCN2 belongs to a large group of transport
proteins that are capable of carrying small and lipid soluble molecules in blood
circulation. It has two membrane receptors, megalin/glycoprotein GP330, which binds
human LCN2 and SLC22A17 or 24p3R, which forms complexes with mouse Lcn2
protein. LCN2 is encoded by a gene located at chromosome locus 9q34.11. LCN2 was
initially isolated from neutrophil granules released at site of infection and
inflammation in human and from mouse kidney cells. LCN2 kills bacteria by iron
depletion during antibacterial innate immune response via sequestering bacterial ferric
siderophores enterobactin (Ent). It has a protective role in infection, inflammation,
injury and other forms of cellular stress. In addition, it is able to interact with and
stabilize matrix metalloproteinase-9 in human neutrophils. Tissue localization and the
effect of LCN2 were studied in streptozotocin-induced diabetic rats using
morphological, physiological, biochemical and molecular biology techniques. This
study shows that LCN2 is co-localized with insulin in normal and diabetic pancreatic
β-cells. In addition, LCN2 significantly reduced the plasma levels of alanine
aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin,
cholestrol, triglycerides, low density lipoprotein and improved the levels of high
density lipoprotein and total protein after the onset of diabetes. LCN2 treatment
decreased the plasma levels of BUN, Urea and LIPC in diabetic animals. Moreover,
the levels of insulin, C-peptide, amylin and GIP were significantly increased in
diabetic rats treated with LCN2. Furthermore, LCN2 showed a significant antioxidant
activity by increasing glutathione reductase, super oxide dismutase and catalase levels
in pancreatic tissue of normal and diabetic animals, as well as their levels in the serum.
In vitro observations show that LCN2 at a concentration of 10-8 M and 10-12 M caused
large and significant increases in insulin release from the INS-1 rat insulinoma cell
line. In conclusion, LCN2 ameliorates the acute and chronic complications of diabetes
mellitus and appears to be a promising adjuvant therapy in the management of DM.
Keywords: Diabetes mellitus, lipocalin-2, metabolic parameters, rat, hormones,
electron microscopy.

vii

)Title and Abstract (in Arabic

ﯾﺨﻔﻒ ﻟﯿﺒﻮﻛﺎﻟﯿﻦ 2-ﻋﻼﻣﺎت وﻧﺘﺎﺋﺞ ﻣﺮض اﻟﺴﻜﺮي ﻓﻲ ﻧﻤﻮذج ﺣﯿﻮاﻧﻲ ﻟﻤﺮض اﻟﺴﻜﺮي
اﻟﻤﻠﺨﺺ

ﻟﯿﺒﻮﻛﺎﻟﯿﻦ 2-ﻣﻜﻮن ﻣﻦ  198ﺣﻤﺾ أﻣﯿﻨﻲ وﯾﺸﺎر اﻟﯿﮫ أﯾﻀﺎ ﺑﺎﻟﺠﯿﻼﺗﯿﻨﯿﺰ اﻟﻤﺮﺗﺒﻂ
ﺑﺎﻟﻠﯿﺒﻮﻛﺎﻟﯿﻦ ،ﺳﺎﯾﺪروﻛﺎﻟﯿﻦ و ﯾﻮﺗﯿﺮوﻛﺎﻟﯿﻦ .ﻟﯿﺒﻮﻛﺎﻟﯿﻦ 2-ﯾﻨﺘﻤﻲ ﻟﻌﺎﺋﻠﺔ اﻟﻠﯿﺒﻮﻛﺎﻟﯿﻦ وھﻲ ﻣﺠﻤﻮﻋﺔ ﻣﻦ
اﻟﺒﺮوﺗﯿﻨﺎت اﻟﺘﻲ ﺗﻨﻘﻞ اﻟﺠﺰﯾﺌﺎت اﻟﺼﻐﯿﺮة ﻣﺜﻞ ااﺣﻤﺎض اﻟﺪھﻨﯿﺔ ،اﻟﺒﺮوﺳﺘﺎﺟﻼﻧﺪﯾﻦ ،اﻟﺮﯾﺘﯿﻨﻮﯾﺪات،
اﻟﻤﻨﺸﻄﺎت واﻟﮭﺮﻣﻮﻧﺎت .ﻟﺪى اﻟﻠﯿﺒﻮﻛﺎﻟﯿﻦ 2-اﺛﻨﯿﻦ ﻣﻦ اﻟﻤﺴﺘﻘﺒﻼت اﻟﻐﺸﺎﺋﯿﺔ اﻟﻤﺴﺘﻘﺒﻞ  24ﺑﻲ  3و
اﻟﻤﺴﺘﻘﺒﻞ ﻣﯿﺠﺎﻟﯿﻦ .ﺗﻢ ﻋﺰل ﻟﯿﺒﻮﻛﺎﻟﯿﻦ 2-ﻓﻲ اﻟﺒﺪاﯾﺔ ﻣﻦ ﺣﺒﯿﺒﺎت اﻟﺨﻼﯾﺎ اﻟﺘﻲ ﺗﻢ اطﻼﻗﮭﺎ ﻓﻲ ﻣﻮﻗﻊ
اﻟﻌﺪوى واﻻﻟﺘﮭﺎب ﻓﺎﻻﻧﺴﺎن وﻣﻦ ﺧﻼﯾﺎ اﻟﻜﻠﻰ ﻓﺎﻟﻔﺌﺮان .ﻟﯿﺒﻮﻛﺎﻟﯿﻦ 2-ﻟﮫ دور وﻗﺎﺋﻲ ﻓﺎﻟﻌﺪوى
واﻻﻟﺘﮭﺎﺑﺎت وﯾﻘﺘﻞ اﻟﺒﻜﺘﯿﺮﯾﺎ ﻋﻦ طﺮﯾﻖ اﺳﺘﻨﻔﺎذ اﻟﺤﺪﯾﺪ ،ﺑﺎﻹﺿﺎﻓﺔ اﻟﻰ ذﻟﻚ ﻓﮭﻮ ﻗﺎدر ﻋﻠﻰ اﻟﺘﻔﺎﻋﻞ
ﻣﻊ ﻣﯿﺘﺎﻟﻮﺑﺮوﺗﯿﻨﯿﺰ . 9-ﺗﻤﺖ دراﺳﺔ ﻟﯿﺒﻮﻛﺎﻟﯿﻦ 2-وﺗﺄﺛﯿﺮه ﻋﻠﻰ اﻻﻧﺴﺠﺔ واﻟﺨﻼﯾﺎ ﻓﻲ اﻟﻔﺌﺮان اﻟﻤﺼﺎﺑﺔ
ﺑﺪاء اﻟﺴﻜﺮي ﻋﻦ طﺮﯾﻖ اﻟﺴﺘﺮﺑﺘﻮزوﺗﻮﺳﯿﻦ .ﺑﺎﺳﺘﺨﺪام ﺗﻘﻨﯿﺎت اﻟﺒﻮﻟﻮﺟﯿﺎ اﻟﻤﻮرﻓﻮﻟﻮﺟﯿﺔ أظﮭﺮت
اﻟﺪراﺳﺔ اﻧﮫ ﯾﺘﻢ ﺗﻮاﺟﺪ اﻟﻠﯿﺒﻮﻛﺎﻟﯿﻦ 2-ﻣﻊ اﻻﻧﺴﻮﻟﯿﻦ ﻓﻲ ﺧﻼﯾﺎ اﻟﺒﻨﻜﺮﯾﺎس اﻟﻄﺒﯿﻌﯿﺔ وﺑﻨﻜﺮﯾﺎس اﻟﻔﺌﺮان
اﻟﻤﺼﺎﺑﺔ ﺑﺎﻟﺴﻜﺮي .ﺑﺎﻹﺿﺎﻓﺔ ﺑﻌﺪ ظﮭﻮر ﻣﺮض اﻟﺴﻜﺮي اﻟﻌﻼج ﻋﻦ طﺮﯾﻖ ﻟﯿﺒﻮﻛﺎﻟﯿﻦ 2-ﻗﺎدر ﺑﺸﻜﻞ
ﻛﺒﯿﺮ ﻋﻠﻰ ﺧﻔﺾ ﻣﺴﺘﻮﯾﺎت اﻟﺒﻼزﻣﺎ ﻟﻠﻜﻮﻟﯿﺴﺘﺮول ،ﺗﺮاﯾﻘﻠﯿﺴﯿﺮاﯾﺪ ،ﻟﯿﺒﻮﺑﺮوﺗﯿﻦ ﻣﻨﺨﻔﺾ اﻟﻜﺜﺎﻓﺔ،
ﺑﯿﻠﯿﺮوﺑﯿﻦ ،واﻧﺰﯾﻤﺎت اﻟﻜﺒﺪ ك اﻻﻧﯿﻦ اﻣﯿﻨﻮﺗﺮاﻧﺴﻔﯿﺮاﯾﺰ و اﺳﺒﺮاﺗﯿﺖ اﻣﻮﻧﻮﺗﺮاﻧﺴﻔﯿﺰ .و أﯾﻀﺎ ﻣﻦ
ﺗﺤﺴﯿﻦ ﻣﺴﺘﻮﯾﺎت اﻟﺒﺮوﺗﯿﻦ اﻟﻜﻠﻲ و ﺗﻤﻜﻦ أﯾﻀﺎ ﻣﻦ رﻓﻊ ﻣﺴﺘﻮﯾﺎت اﻻﻧﺴﻮﻟﯿﻦ .ﺑﺎﻹﺿﺎﻓﺔ اﻟﻰ ذﻟﻚ
اﻟﻌﻼج ﻣﻊ ﻟﯿﺒﻮﻛﺎﻟﯿﻦ 2-أظﮭﺮ ﻧﺸﺎطﺎ ﻛﺒﯿﺮا ﻛﻤﻀﺎد ﻟﻸﻛﺴﺪة ﻋﻦ طﺮﯾﻖ رﻓﻊ ﻣﺴﺘﻮﯾﺎت اﻻﻧﺰﯾﻤﺎت
اﻟﻤﻀﺎدة ﻟﻸﻛﺴﺪة ﻓﻲ اﻟﺒﻼزﻣﺎ وأﻧﺴﺠﺔ اﻟﺒﻨﻜﺮﯾﺎس .أظﮭﺮت دراﺳﺎﺗﻨﺎ اﻟﻤﺨﺘﺒﺮﯾﺔ أن ﻣﺼﻞ
اﻟﻠﯿﺒﻮﻛﺎﻟﯿﻦ 2-ﺗﺴﺒﺐ ﺑﺰﯾﺎدات ﻛﺒﯿﺮه وھﺎﻣﺔ ﻓﻲ اﻓﺮاز اﻻﻧﺴﻮﻟﯿﻦ ﻣﻦ ﺧﻂ ﺧﻼﯾﺎ اﻻﻧﺴﻮﻟﯿﻦ ﺑﺘﺮﻛﯿﺰ
 10-^12و  .10-^8ﻓﻲ اﻟﺨﺘﺎم ﯾﺨﻔﻒ ﻟﯿﺒﻮﻛﺎﻟﯿﻦ 2-اﻟﻤﻀﺎﻋﻔﺎت اﻟﺤﺎدة واﻟﻤﺰﻣﻨﺔ ﻟﻤﺮض اﻟﺴﻜﺮي
وﯾﺒﺪو اﻧﮫ ﻋﻼج ﻣﺴﺎﻋﺪ واﻋﺪ ﻓﻲ إدارة ﻣﺮض اﻟﺴﻜﺮي.
ﻣﻔﺎھﯿﻢ اﻟﺒﺤﺚ اﻟﺮﺋﯿﺴﯿﺔ :ﻣﺮض اﻟﺴﻜﺮي ،ﻟﯿﺒﻮﻛﺎﻟﯿﻦ ،2-اﻟﺠﺮذان ،اﻟﮭﺮﻣﻮﻧﺎت ،ﻣﺆﺷﺮات اﻻﯾﺾ،
اﻟﻤﺠﮭﺮ اﻻﻟﯿﻜﺘﺮوﻧﻲ.
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Chapter 1: Introduction
1.1 Diabetes Mellitus
Diabetes mellitus (DM) is a complex and heterogeneous group of endocrine
disorders. All types of diabetes mellitus share hyperglycemia as a common outcome
and disturbances of glucose, lipid, and protein metabolism. Absolute or partial loss of
insulin action and/or insulin secretion (Bradley et al., 1998), and depletion in
functional β- cell mass are considered to be the key mechanisms that lead to the
development of the disease (Cnop et al., 2005). The American Diabetes Association
(ADA) defines type 1 diabetes mellitus (T1DM) as autoimmune β-cell destruction,
usually leading to absolute insulin deficiency. ADA refers to type 2 diabetes mellitus
(T2DM) as a progressive loss of β-cell insulin secretion, frequently occurring on the
background of insulin resistance, and gestational diabetes mellitus (GDM) as diabetes
diagnosed in the second or third trimester of pregnancy that was not clearly overt
diabetes prior to gestation. Other types of diabetes include MODY, pancreatic
diabetes, and drug- or chemical-induced diabetes. All types are diagnosed on the basis
of hyperglycemia, however, each type has different diagnostic marker. In type 1, which
results from autoimmune destruction of beta cells, the presence of pancreatic
autoantibodies in the blood is an important diagnostic marker. MODY which is a
monogenic type of diabetes caused by a single gene defects, sequencing is used as a
diagnostic test to sequence the known monogenic diabetes genes to determine the
pathological variant. Haemochromatosis, an inherited condition leading to iron
overload and accumulation can damage multiple organs including the pancreas if not
treated. This condition may lead to DM and can be diagnosed by ferritin and gene
sequencing. Cushing syndrome, which is a hormonal disorder due to a long-term
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exposure to high amounts of cortisol may induce hyperglycemia and this type of
diabetes can be diagnosed using dexamethasone suppression test. However, in type 2
diabetes there is no specific diagnostic test to identify it other than the exclusion of the
other causes. Classifying patients with diabetes mellitus into subgroups based on
disease progression and risk of complications are being investigated (Ahlqvist et al.,
2018; Pearson, 2019).
1.2 Epidemiology of DM
Based on the International Diabetes Federation, 9.3% of the adult population
aged 20-79 years globally are considered diabetic which is equivalent to 463 million
in which the majority 79.4% account for individuals from low to middle income
regions. The prevalence of the disease is estimated to further increase to 578.4 million
by 2030 and by 2045, 700.2 million adults aged 20 - 79 years, will suffer from diabetes
(Atlas, 2019). Among all individuals diagnosed with diabetes, only 10 to 15% have
T1DM, and the majority of the diagnosed population is considered type 2 diabetic
which is the most common form. The prevalence of type 1 diabetes is increasing
among all age groups specifically in children which is doubling every 25 years
(Patterson et al., 2019; Pociot & Lernmark, 2016). It is estimated that approximately
90,000 children are diagnosed yearly. Recently, it has been shown that DM causes an
average loss of 11 to 12 years of life expectancy (Livingstone et al., 2015). This loss
increases in patients who developed the disease earlier in life. For example, patients
who are diagnosed before the age of 15 years live 2.5 years less than those diagnosed
after the age of 30 years.
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1.3 DM Classification and Diagnosis
1.3.1 Type 1 Diabetes Mellitus
T1DM, also known as insulin dependent diabetes, juvenile-onset diabetes and
ketosis-prone diabetes is caused by autoimmune-mediated β-cell destruction and
apoptosis, leading to the loss of β-cell ability to produce insulin and leading to a
lifelong need for treatment with exogenous insulin. The disease is the consequence of
invading or resident macrophages and T cells, which secretes chemokines and
cytokines in the islet microenvironment and deliver cell–cell pro-apoptotic signals, or
by stressed, injured or dying β- cells that attract and activate immune cells to the islets
(Eizirik et al., 2009; Gonzalez-Duque et al., 2018). The etiology of βcelltargeted
autoimmunity depends on the patient’s genetic background, age and multiple
environmental factors, including viral infections and diet. This, in majority of cases
occurs years before the eventual development of hyperglycemia and the disease
symptoms (DiMeglio et al., 2018; Ilonen et al., 2019). Pathogenic association between
immune cells and β- cells leads to inflammation and increased β- cell destruction by
apoptosis (Eizirik et al., 2009; DiMeglio et al., 2018; Todd, 2010). Several months to
years before T1DM onset the presence of autoantibodies is detected, which acts as
biomarkers for the development of autoimmunity. Those autoantibodies associated
with the disease onset, targets most of the islet antigens including insulin and its
precursor preproinsulin (PPI), 65 kDa glutamic acid decarboxylase (GAD65; also
known as GAD2), insulinomaassociated protein 2 (IA2) and zinc transporter 8
(ZNT8) (Gonzalez-Duque et al., 2018; Thomaidou et al., 2018; DiMeglio et al., 2018).
Individuals with specific HLA genotypes (which encode MHC proteins) - that is,
HLADR and HLADQ genotypes (HLADRDQ) — have an increased risk of
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developing two or more autoantibodies and T1DM (DiMeglio et al., 2018; QuispeTintaya, 2017). Anti-insulin or antiGAD65 βcell autoantibodies are the earliest
autoantibodies to appear during childhood, which target insulin and GAD65. However,
rarely IA2 autoantibody or ZNT8 autoantibody are detected first (Thomaidou et al.,
2018; DiMeglio et al., 2018). What influences the development of the first βcell
targeting autoantibodies is still investigated in different follow-up studies of children
from birth (Gonzalez-Duque et al., 2018; Ilonen et al., 2019; Todd, 2010). A staging
classification system for the pathogenesis of T1DM has been suggested based on the
detection of autoantibodies, and the progression to βcell destruction. The first stage
recognized is the presence of β- cell autoantibodies in normoglycemic people, the
second stage shows dysglycemia in the presence of β- cell autoimmunity, and the third
stage as clinical T1DM due to the symptoms associated with hyperglycemia. Up to
date T1DM cannot be prevented or completely cured via currently available
therapeutic approaches (DiMeglio et al., 2018; Greenbaum et al., 2018). However a
delay on disease establishment has been detected by approximately 2 years when using
monoclonal antibody against CD3 which is present on the surface of CD8+ T cells that
dominate the pancreatic immune infiltrated cells leading to βcell destruction in T1DM
in stage 2 patients (Herold et al., 2019).
1.3.2 Type 2 Diabetes Mellitus (T2DM)
T2DM accounts for the majority, more than 80% of all diagnosed diabetic
patients. The pathogenesis of type 2 diabetes mellitus (T2DM) is caused by two key
disturbances one is relative insulin deficiency due to β-cell dysfunction and the other
is insulin resistance (Weyer et al., 1999; Lyssenko et al., 2005; Cnop et al., 2007).
Multiple key risk factors lead to the rise in the global epidemic of type 2 diabetes
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mellitus including obesity, aging, poor activity, sedentary lifestyle and energy dense
diets (Zheng et al., 2018). These have resulted in four-fold rise in the number of
patients during the last 40 years (Risk & Collaboration, 2016). T2DM is linked with
significant morbidity and mortality. On average 6 years loss in life span is observed,
and in cases of disease onset at younger age the loss in life expectancy elevates up to
12 years (Sattar et al., 2019). However, the management of the chronic complications
has improved over time. No clear diagnostic criteria exist for T2DM which makes it
an ill-defined form of the disease. Clustering approaches using age at diagnosis, BMI,
HbA1c, HOMA estimates of β- cell function and insulin resistance, and glutamic acid
decarboxylase autoantibodies have subtyped patients into moderate or severe forms of
T2DM, with a predominance of insulin resistance or insulinopenia (Ahlqvist et al.,
2018).
1.3.3 Islet Morphology
Knowledge on islet morphology and the pathophysiology of diabetes mellitus
are obtained from restricted studies of human pancreas collected at necropsy and on
murine models, such as non-obese diabetic (NOD) mice, ob/ob and db/db mouse
models of obesity and T2DM, and the GK rat model of T2DM. Data from these models
have established diabetic model for the human disease to a limited extent. The
emerging of the Network for Pancreatic Donors with Diabetes (Pugliese et al., 2014)
in addition, the systematic organization of the Exeter Archival Diabetes Biobank
provided access to ~500 pancreas in good condition from patient with T1DM and nondiabetic individuals as controls from both necropsy and organ donors, representing
variant ages of disease onset and duration (Rodriguez-Calvo et al., 2018). Various
methods, including the integrated analysis of histology, physiology, mass cytometry,
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genomics and immunology of T1DM organ donors (Kaestner et al., 2019), provides
better ways to collect information from these samples.
1.3.4 Characteristics of Human Β- Cells in T1DM and T2DM
Key findings obtained from histological studies conducted on T1DM patients,
revealed elevated heterogeneity of inflammation and β- cell destruction. Some cell
clusters contain islets lacking β-cells, and other clusters have almost normal-looking
islets and/or β- cell content, with fewer infiltrating immune cells (Rodriguez-Calvo et
al., 2018; Morgan & Richardson, 2018). Moreover, hyperexpression of class I HLA
(Morgan & Richardson, 2018) and β- cell stress markers such as ER stress (Marhfour
et al., 2012) were detected particularly in insulin-expressing islets. In T1DM patients
who are diagnosed within 0–6 years after onset, β- cells are found to express markers
of cellular aging, as CDKN1A and β-galactosidase, as well as IL-6 and serpine 1,
suggesting an inflammatory ageing-associated secretory phenotype (Thompson et al.,
2019). In a study conducted on T1DM mouse, clearance of senescent β- cells decreases
the incidence of diabetes mellitus (Thompson et al., 2019). In another study of human
T1DM, loss of the β-cell markers insulin, proinsulin and amylin, precedes β-cell death
(Damond et al., 2020). Islets extracted from NOD mice exposed to severe insulitis are
non-functional during extraction, but they become functional once freed from the
infiltrating immune cells in 7 days in culture (Strandell et al., 1990). Moreover, islets
extracted from patients with T1DM after 5–6 days in culture has regained their
function (Krogvold et al., 2015; Marchetti et al., 2000). Different studies showed
impairment of α cell gene expression and function in T1DM patients islets and cells
(Brissova et al., 2018; Mastracci et al., 2018) in comparison with islets from nondiabetic individuals. Alpha cells are not targeted by the autoimmune destruction in
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T1DM and shows resistance to stress stimulated by metabolic disorders (Brissova et
al., 2018; Marroqui, Masini, et al., 2015) or virus infection (Marroqui, Lopes, et al.,
2015) compared to β- cells. However, the causes of α-cell impairment and dysfunction
require further investigations, but the change in islet morphology and loss of β- cell–
α- cell contacts is believed to have an influence. Insulin secretion at low levels, is
found in 80% T1DM patients with average of 21 years duration of the disease, as
evaluated by urinary C-peptide. Moreover, T1DM patients with no C-peptide detection
were still producing proinsulin (Sims et al., 2019). Recent studies suggest that other
islet cells in specific α-cells begins to express low levels of insulin after β-cell
destruction (Lam et al., 2019). This is supported by findings in murine study showing
trans-differentiation of α-cells to β-cells after β- cell extraction (Thorel et al., 2010) or
by inhibiting the α-cell transcription factor ARX (Courtney et al., 2013). The immune
system plays key role in β- cell function and survival (Eizirik et al., 2009). The
presence of cytokines at different phases of insulitis in the islet environment is
significantly upregulated. For instance during the early stages of inflammation, type I
interferons level is high, and at later stages, the blood concentration of IFNγ, IL-1β,
tumor necrosis factor (TNF), and IL-17 rises (Eizirik et al., 2009). This triggers ER
stress, changes in alternative splicing (Ortis et al., 2010; Eizirik et al., 2012) and
elevation of HLA class I (Morgan & Richardson, 2018; Marroqui et al., 2017). All of
these, in addition to elevated β-cell synthesis of chemokines and cell death, are the
cause of increased β-cell neoantigens in response to infiltrating immune cells, leading
to increase in the immune assault (Eizirik et al., 2009; Gonzalez-Duque et al., 2018).
In T2DM, pancreatic islets experience a loss of β-cell mass ranging from 25–
60%, elevated β- cell apoptosis, decreased pancreatic insulin and higher amyloid
deposition by islet amyloid polypeptide which in turn leads to ER stress (Raleigh et
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al., 2017) compared with non-diabetic individual (Rahier et al., 2008; Del Guerra et
al., 2005). Alpha cell mass overall is unaltered in T2DM (Henquin & Rahier, 2011)
and β-cell mass loss is minimal in new onset cases and increases with longer duration
of the disease (Rahier et al., 2008). However, β- cell function is ultimately impaired at
T2DM onset, it is predicted to decline by ~80% (Cnop et al., 2007; Cnop et al., 2007;
Utzschneider et al., 2009). These findings indicate that β-cell dysfunction is a primary
player in T2DM pathogenesis and happens independently of β-cell loss. The causes
for the impairment of β-cell function and β-cell survival in T1DM and T2DM differs.
For instance, cytokines can stimulate β-cell dysfunction and death in T1DM, while
free fatty acids (FFAs) could induce ER stress and cause β-cell dysfunction and
destruction in T2DM. However, these effects could be exerted through similar
downstream signal transduction pathways. Large body of evidence indicates that
increased β-cell ageing arises in T2DM. β- cells are long lived cells with restricted
neogenesis and replication. As demonstrated by (Tamura et al., 2016) adult α and β
cells telomere shortening is highly detected before the age of 20 years and decreases
thereafter, indicating replicative senescence of postmitotic adult β- cells. Increased
telomere exhaustion was detected in β-cells in T2DM (Tamura et al., 2014). β- cells
cellular aging is characterized by acid β- galactosidase and p16INK4A expression
which in turn induces the secretion of pro-inflammatory cytokines and loss of β- cell
markers. In type 2 diabetic patient islets, elevated β- galactosidase expression in cells
were noticed and β-cell expressing β-galactosidase showed upregulation in
p16INK4A, CCL4 and IL-6 expression (Cristina et al., 2019). However, cellular aging
and senescence contribution to β-cell dysfunction in T2DM is still unclear.
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1.4 Management of Diabetes Mellitus
1.4.1 Lifestyle Modification
The lifestyle of an individual plays an important role in the person’s health,
especially the type and quality of the food consumed. Ingestion of nutrients with low
glycemic index in key to reducing diabesity (Brand-Miller et al., 2003). It has been
reported that physical inactivity and/or a sedentary lifestyle are major risk factors for
the development of obesity and insulin resistance. Physical activity coupled with
dietary modification are beneficial to improving reducing obesity and increasing
insulin sensitivity in target cells such as muscle and liver (Horton, 1988). A metaanalysis on the effects of low-carbohydrate diets on CVD risk factors showed a large
and significant decrease in total body weight, BMI, abdominal circumference, blood
pressure (systolic and diastolic), triglycerides, fasting glucose, HbA1C, and CRP. All
of these were also associated with increased levels in the level of HDL, the good
cholesterol (Santos et al., 2012). This beneficial effect of lifestyle modification and
diet showed intense physical activity coupled with appropriate diet resulted in
significant weight reduction and decreased levels of glycated hemoglobin (HbA1c).
1.4.2 Pharmacotherapy
A large number of both oral and injectable drug classes are available to control
both types of DM. Hyperglycemia, the hallmark of the disease, is a result of different
metabolic events. In type 2 diabetes, this include diminished insulin secretion and
elevation in glucagon production by the pancreatic islet cells, increased hepatic output
of glucose, impairment of GLP-1 and GIP secretion and/or action, elevation in insulin
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resistance and decline in β-cell mass and function (Weyer et al., 1999; Dunning &
Gerich, 2007; Toft-Nielsen et al., 2001).
1.4.2.1 Insulin
In T1DM, after meal ingestion, insulin secretion is not stimulated, however,
glucagon secretion is maintained. Without proper exogenous insulin replacement, the
endogenous glucose production will not be controlled, glycogen synthesis will be
decreased with elevation in systemic glucose levels. Administration of exogenous
insulin mimics the native insulin hormone and normalizes all these abnormalities.
Glargine and detemir are two widely used long acting human insulin analogues.
Detemir absorption is slow from the subcutaneous tissue and circulation due to the
fatty acid chain, which binds to circulating albumin. Glargine on the other hand is
injected as an acidic solution, in neutral PH crystals are formed and they are absorbed
slowly. Both are used once either morning or evening to achieve normal glucose levels,
with a decreased hypoglycemic risk. Mealtime insulin, which are short-acting insulin
preparations include glulisine, aspart and lispro. These insulin preparations are
administered at meals time. They have shown reduced hypo- and hyperglycemia states,
however, several clinical trials showed a modest reduction on HbA1c by these agents
(Kaufman, 2003).
1.4.2.2 Metformin
Metformin is an insulin sensitizer commonly used for the treatment of T2DM
in adult and children. It is one of the most studied and prescribed drug in the global
pharmaceutical market. Metformin can reduce weight and HbA1c when combined
with lifestyle interventions (Meneghini et al., 2011; Domecq et al., 2015). Metformin
is able to reduce weight because it blocks hepatic gluconeogenesis, reduces appetite,
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stimulates and increases insulin sensitivity in all peripheral tissues. It is not completely
clear how metformin exerts its effect, however, it has been reported that it inhibits
mitochondrial respiratory chain and cAMP synthesis with a concomitant reduction in
protein kinase A activity. The activity of mitochondrial glycerophosphate
dehydrogenasea and adenosine monophosphate (AMP)-activated protein kinase
(AMPK) are also modified accordingly (Zhou et al., 2001; Madiraju et al., 2014; Rena
et al., 2013). A clinical trial conducted by the Diabetes Prevention Program showed
that metformin reduced the incidence of type 2 diabetes by 31% in high risk obese
patients who had grossly impaired glucose tolerance (Aroda et al., 2017). Metformin
is also a useful drug in the treatment of a large variety of health problems associated
with diabesity. Metformin, combined with lifestyle modification is used in the
treatment polycystic ovary syndrome (PCOS) (Naderpoor et al., 2015), gestational
diabetes mellitus (Jiang et al., 2015), non-alcoholic fatty liver disease (NAFLD)
(Chalasani et al., 2012), and even cancer (Wu et al., 2015).
1.4.2.3 α-Glucosidase Inhibitors
Acarbose, voglibose and miglitol are the three main drugs used to inhibit αglucosidase found in the epithelium of the small intestine. This enzyme cleaves
monosaccharides from polysaccharides to promote their absorption by the gut
epithelium. α-glucosidase inhibitors thus prevent the absorption of carbohydrate from
the small intestine. In a new meta-analysis study, α-glucosidase inhibitors significantly
reduced HbA1c, 2-h postprandial glucose and bodyweight when compared to placebo.
Unfortunately, the high prevalence of ﬂatulence and diarrhea has prevented the wide
use of this class of drugs (Gao et al., 2018).
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1.4.2.4 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Dipeptidyl Peptidase-4 (DPP-4) inhibitors increase the level of incretin by
inhibiting DPP-4, the enzyme that degrades GLP-1 and glucose-dependent
insulinotropic polypeptide (GIP). (Herman et al., 2006). GLP-1 and GIP enhance
glucose-dependent pancreatic insulin response, suppress glucagon release, and
increase satiety (Ahrén, 2013; Herman et al., 2006). Several clinical and pre-clinical
studies have shown that the outcome of the signs and symptoms of DM is better after
the use of DPP-4 inhibitors. DPP-4 inhibitors promote glycemic control, insulin
secretion, and β-cell function in animal models (Pospisilik et al., 2002) and in subjects
with T2DM (Herman et al., 2006). In patients with type 2 diabetes, DPP-4 inhibitors
reduced postprandial glucose, fasting plasma glucose and HbA1c levels with low risk
of hypoglycemia and weight gain. It also promote pancreatic beta cell function with
no association with insulin resistance (Lyu et al., 2017). Currently available DPP-4
inhibitors include but not limited to sitagliptin, vildagliptin, saxagliptin, linagliptin,
alogliptin, gemigliptin, trelagliptin, omarigliptin, evogliptin, gosogliptin, teneligliptin
and anagliptin. With the use of this drug, no weight gain has been detected and an
average HbA1c decrease of 0.5–1.0% has been reported (Pappachan, 2015).
1.4.2.5 GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) are two gut secreted peptide hormones from L-cells and K-cells,
respectively. They are released following a meal ingestion and play a key role in
promoting insulin secretion and synthesis based on glucose levels. In addition, they
suppress glucagon production (Baggio & Drucker, 2007) and both hormones have an
additive affect. The GLP-1 agonists are structurally different from the endogenous
GLP-1, and this change in the structure facilitate longer half-lives and resistance to the
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DPP-4 activity, which increases the activity of these agonists. GLP-1 agonists have
the same effect as the endogenous hormone, they lower blood glucose in a dosedependent manner. In addition, they also affect fat accumulation and in part are
associated with weight loss (Baggio & Drucker, 2007; Flint et al., 1998; Radford,
1990). Moreover, several clinical studies indicates that using GLP-1 receptor agonists
lowers systolic blood pressure and exerts cardiovascular protection affect (Fonseca et
al., 2014; Russell-Jones et al., 2009; Marre et al., 2009). Exenatide and liraglutide are
the two drug forms of GLP-1 receptor agonists available in the market. Exenatide is
the ﬁrst GLP-1 receptor agonists to be approved in USA as therapeutic agent for the
treatment of T2DM patients. It is a 39-amino acid synthetic peptide that is 53%
homologous to human endogenous GLP-1 (Diego et al., 2006; Nielsen et al., 2004).
While liraglutide is 97% homologous to the endogenous human GLP-1, with one
amino acid substitution which increases its plasma half-life up to 13 hours (Colagiuri,
2010). Exenatide is injected two times daily one-hour prior to meals and liraglutide is
administrated once-daily (Diego et al., 2006).
1.5 Peptides as Therapeutic Agents
Peptides are naturally occurring compounds which are made of short chain of
amino acids that exert their function by their interaction with their specific receptors
followed by different intracellular events (Vlieghe et al., 2010). The use of peptides as
therapeutic agents has been promising for the treatment of several diseases including
inflammatory diseases, cancer, cardiovascular diseases, and diabetes mellitus.
Oxytocin is the first peptide to be synthesized in 1953 however, in 1982, recombinant
human insulin was the first peptide to be approved for clinical use (Puttagunta & Toth,
1998). Currently about 60 peptide drugs are approved and available in the market. The
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number of peptides investigated as therapeutic agents preclinically and entering
clinical trials is increasing (Dinca et al., 2016). The challenges including the
presentation of poor metabolic stability, membrane permeability and oral
bioavailability associated with peptides was restricting their investigation and
production by pharmaceutical companies in the past. However, recent modification in
drug delivery systems, new formulations, and other fields involved have made it
possible to overcome those disadvantages and make use of their advantages such as
high potency and selectivity of their targets as well as the low toxicity, low
accumulation in tissue and fast clearance, as seen in multiple natural peptide drugs
such as insulin (Anderson & Delgado, 2008; Barabási et al., 2011).
1.6 Lipocalin-2
Lipocalin-2 (LCN2), a novel adipokine consisting of 198 amino acids, is also
known as neutrophil gelatinase-associated lipocalin. Other names associated with
LCN2 include, siderocalin, uterocalin, α1-microglobulin related protein, and 24p3.
LCN2 belongs to large group of proteins that carry small and lipid soluble biological
agents in blood circulation. These hrophobic molecule include steroids, fatty acids,
retinoids, prostaglandins and hormones. (Flower, 1994; Chu et al., 1998). Two cell
surface receptors has been proposed for this protein one is megalin/glycoprotein
GP330 which binds human LCN2 (Hvidberg et al., 2005) and SLC22A17 or 24p3R
which binds mouse Lcn2 protein (Devireddy et al., 2005). LCN2 is encoded by a gene
located at chromosome locus 9q34.11. LCN2 gene produce at least five functional
transcripts that translate into proteins, the most common of which encodes for a 198
amino acid secreted protein. LCN2 was initially isolated from neutrophil granules
released at site of infection and inflammation in human (Flower, 1994; Kjeldsen et al.,
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1993), and from mouse kidney cells. LCN2 is a bacteriostatic agent capable of iron
depletion during antibacterial innate immune response. It does this by degrading the
ferric siderophores enterobactin (Ent) of bacteria (Nairz et al., 2009; Holmes et al.,
2005). It has also been shown that LCN2 has a protective role on the body during the
process of infection, inflammation (Cowland & Borregaard, 1997), injury and tissue
stress. In addition, it is able to interact with and stabilize matrix metalloproteinase-9
(MMP-9) in human neutrophils. The Lcn2 and MMP-9 complex, prevents MMP-9
auto-degradation and upregulate the activity of MMP-9 in vitro. MMP-9 is known for
its ability to degrade the extracellular matrix and basement membranes. This
LCN2/MMP-9 complex is suggested to aid in tumor progression, invasion and
metastasis (Kobara et al., 2013; Triebel et al., 1992). In addition to its bacteriostatic
properties, previous studies in animal models suggest important roles for Lcn2 in many
physiological and pathological processes such as cell differentiation, apoptosis,
organogenesis, inflammation, kidney damage and liver injury, Moreover, it is also
suggested that Lcn2 has a role in cancer progression and metastasis (Candido et al.,
2016). Recent studies have shown that the blood level LCN2 is increased after the
onset of obesity and type 2 diabetes (Yan et al., 2007). Some reports have associated
Lcn2 to insulin sensitivity and glucose metabolism, however, its role in the modulation
of insulin sensitivity, glucose and lipid metabolisms has not been completely
elucidated. Human lipocalin-2 protein is represented in upper case (LCN2), while the
mouse and rat homologues are usually represented in lower case (Ngal or Lcn2) to
differentiate between them (Kjeldsen et al., 2000).
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1.6.1 Structure
Human LCN2 and it is homologues in mouse and rat, contain a 20-amino acid
signal peptide at the N-terminal end of the protein, which is cleaved prior secretion,
followed by the domain where lipocalins bind to their ligands, known as lipocalin
domain. The highly conserved LCN2 structure is comprised of an eight stranded betabarrel that forms a closing calyx in an antiparallel direction which represents the
internal ligand-binding site allowing lipocalins to bind to their ligands. This binding
cavity of LCN2 is significantly larger and polar than other lipocalin proteins and
enables it to bind to cell surface receptors and form macromolecular complexes by
binding to larger and less hydrophobic ligands as mammalian proteins, which in turn
provides key functions in cell regulation, proliferation and differentiation (Goetz et al.,
2000). LCN2 occurs in various molecular forms as a monomer (25-kDa), a disulfidelinked homodimer (46-kDa) and a disulfide-linked heterodimer with human neutrophil
gelatinase B (135-kDa) (Kjeldsen et al., 1993). The amino acid sequence between
NGAL homologues among different species shows that human NGAL have less
identity similarity to the mouse and rat homologues (62% and 63% similarity
respectively). This is very important to note because most of the studies on the function
of LCN2 are done on murine. However, the mouse and human homologue are highly
similar in the architecture domain (Figure 1) and three dimensional structure.
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Figure 1: Human, mouse and rat LCN2 domain architecture showing high degree of
similarity. Consisting of 20-amino acid signal peptide at the N-terminal end of the
protein, which is cleaved prior to secretion. This is followed by the domain where
lipocalins bind to their ligands, known as lipocalin domain or lipocalin fold, which
makes up most of the length of the protein.
1.6.2 Tissue Distribution of Lipocalin 2
LCN2 was first identified and located in the azurophilic neutrophil granules
(Kjeldsen et al., 1993). Following this, several researchs have been conducted to
investigate the expression of LCN2 in various tissues. It has been identified that LCN2
is expressed in several normal tissues including liver, lung, kidney, bone marrow,
adipose tissue, macrophages, thymus, non-neoplastic breast duct, prostate, small
intestine and trachea where almost there is limited to no expression detected of LCN2
in the normal pancreas, endometrial glands, and peripheral blood leucocytes. LCN2 is
however, completely absent from the normal brain, heart, skeletal muscle, spleen,
testes, ovary and colon (Seth et al., 2002; Moreno-Navarrete et al., 2010; Cowland et
al., 2003; Cowland & Borregaard, 1997; Furutani et al., 1998). In comparison to adult
LCN2 is less investigated in infants. An investigation of LCN2 expression in several
human fetal tissue has reported an expression of LCN2 in multiple tissues at different
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weeks of gestation such as in the epidermis of the fetal skin approximately in the 2024 week of gestational age. Afterwards, the expression concentrates toward lower
layers of the skin and becomes progressively receded toward the hair follicles
(Mallbris et al., 2002). In murine tissues the expression of LCN2 has been investigated
intensively. In the embryo, LCN2 is expressed in the hypertrophic and
perihypertrophic regions of the developing cartilage (Owen et al., 2008). It has been
reported to be expressed in various tissues of the adult murine such as luminal
epithelium and glands of the mouse uterus (Huang et al., 1999) bone marrow, liver,
spleen, testis, lung and no expression was detected in the normal liver, heart, kidney,
small bowel, thymus, brain or in the fetus liver (Aigner et al., 2007). The expression
of LCN2 is strongly upregulated in the tissues as well as the body fluids in various
pathological conditions, including inﬂammatory and metabolic disorders especially in
several organs such as liver, heart, lungs, bone marrow, kidney, and spleen (BorkhamKamphorst et al., 2011; Aigner et al., 2007).
1.6.2.1 Adipose Tissue
Several studies have reported LCN2 expression in adipose tissue (Lin et al.,
2001; Kratchmarova et al., 2002; Wang et al., 2007). Reports have shown that the
expression of LCN2 is elevated during adipoctyogenesis in 3T3-L1 cell line. A study
by Yan et al., showed that white adipose tissue (WAT) was the major source of LCN2
expression and reported its absence in brown adipose tissue (BAT) in wild-type male
mice. They suggested that obesity regulates its expression (Yan et al., 2007).
1.6.2.2 Liver
The liver is considered the main LCN2 source during infection or post-partial
hepatectomy (PHx). The induction of more than 30-40 folds of LCN2 mRNA
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expression was monitored in the liver as well as a significant increase in serum LCN2
levels after 24 and 36 hours post-bacterial challenge by the administration of K.
pneumoniae (1×103 CFU) and E. coli (1×107 CFU). Moreover, surgical stress on the
induction of LCN2 expression was investigated using the PHx model revealing that
serum LCN2 protein and hepatic LCN2 mRNA levels were significantly increased
post-PHx (Wazen et al., 2015).
1.6.2.3 Brain
Astrocytes are star-shaped glial cell of the central nervous system. They are
responsible of the metabolic and trophic support to neurons and the modulation of
synaptic activity. In response to a brain injury, astrocytes undergo reactive
astrocytosis. LCN2 is an autocrine mediator of reactive astrocytosis performing
multiple roles in regulating cell death, morphology, and migration of astrocytes. Lcn2
expression and secretion increased after inflammatory stimulation in cultured
astrocytes. As shown by Western blot analysis in C6 glia cells and primary astrocytes,
the expression and secretion of Lcn2 was markedly increased after the treatment with
different inflammatory stimuli (Lee et al., 2009)
LCN2 expression is upregulated in patients with traumatic brain injury (TBI)
in both, the injured tissue of the brain as well as the plasma serum of the patients.
Furthermore, LCN2 expression is positively correlated with the severity of traumatic
brain injury, suggesting that LCN2 can be used as a biomarker for the severity of TBI.
Since this disease can cause serious complication to the patients leading to disability
and mortality (Zhao et al., 2016). In the animal model LCN2 is expressed as well in
endothelial cells, basal ganglia post ICH, corpus callosum after cerebral ischemia
(Marques et al., 2012).
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1.6.2.4 Lung
LCN2 mRNA expression has been identified in human lung and trachea where
it is localized to goblet cells and ciliated epithelial cells in the normal bronchial and
alveolear type II pneumocytes derived cell line A549. Moreover, a significant increase
in LCN2 mRNA expression was detected in bronchial epithelial cells and alveolar type
II pneumocytes during lung inflammation (Cowland et al., 2003). This was supported
by another study which showed an elevation in LCN2 mRNA expression and serum
levels monitored in the lung after 24 and 36 hours post-bacterial challenge by the
administration of K. pneumoniae (1×103 CFU) and E. coli (1×107 CFU) (Wazen et al.,
2015).
1.6.2.5 Kidney
LCN2 expression is upregulated in both acute and chronic kidney damage.
LCN2 has been demonstrated as a potential early biomarker for kidney injuries in
several studies (Bennett et al., 2008; Kümpers et al., 2010; Mishra et al., 2003). Human
and mouse transplantation studies reveal that LCN2 expression is derived from the
damaged nephrons (Ashraf et al., 2016). Another potential source of systemic LCN2
is neutrophils and macrophages (Hvidberg et al., 2005). Chronic kidney disease (CKD)
in addition is also associated with marked upregulation in LCN2 levels in tissue and
body fluids (blood and urine) (Stenvinkel, 2010; Viau et al., 2010).
1.6.2.6 Bone Marrow
Strong Expression of LCN2 mRNA is detected in human bone marrow cells
(myelocytes and metamyelocytes) (Cowland & Borregaard, 1999). In cells of
intermediate maturity, Costa et al., found that LCN2 was expressed during osteoblast
differentiation (Costa et al., 2013).
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1.6.2.7 Skin
The activated keratinocytes in the epidermis and infiltrated neutrophils in the
dermis of psoriatic human patients and murine showed higher mRNA and protein
expression levels of LCN2 compared to those in normal controls (Shao et al., 2016).
Interestingly, treating psoriatic patients with calcipotriol for 14 days resulted in no
change in LCN2 expression in these lesions. While once the lesions healed, the
expression of LCN2 dropped by itself, suggesting that LCN2 expression is regulated
by the disease process (Mallbris et al., 2002).
1.6.2.8 Neutrophils
LCN2 is constitutively expressed in human neutrophils and was initially
isolated as a 25-kDa neutrophil protein. During inflammation LCN2 is secreted by
prepackaged neutrophil granules (Kjeldsen et al., 1993)
1.6.2.9 Heart
Previous studies has proved that Lcn2 is upregulated in ischemia-reperfusion
processes, coronary heart disease and myocardial infarction (Yndestad et al., 2009;
Choi et al., 2008; Hemdahl et al., 2006; Aigner et al., 2007) suggesting that it is a
promising and useful biomarker of the severity and mortality of heart diseases.
Another study demonstrated that Lnc2 expression has been detected in the mouse
cardiomyocytes. Moreover, hypoxia induced the mRNA expression and protein levels
of LCN2 in HL-1 cells (Xiong et al., 2016). Furthermore, a study by Aigner and
colleagues revealed that LCN2 mRNA expression and protein levels were significantly
upregulated in heterotopic heart transplanted murine (Aigner et al., 2007).
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1.6.2.10 Pancreas
LCN2 protein levels were markedly higher in pancreatic juice in patient with
chronic pancreatitis and pancreatic cancer (Kaur et al., 2013). Moreover, ELISA
analyses of LCN2 showed high levels in mice with mild acute pancreatitis (MAP) and
severe acute pancreatitis (SAP) compared to control (Chakraborty et al., 2010). In
another study they have tested different markers in the serum of KPC mice model to
determine their expression. mouse CXCL16, mouse TIMP1, and mouse LCN2 ELISA
analysis revealed a significant elevation in serum levels in mice with PanIN2/3 lesions
or invasive PC compared to controls. However, LCN2 was the most promising serum
biomarker for the pancreatic cancer in mice (Slater et al., 2013).
1.6.2.11 Spleen
LCN2 has a low expression in the normal spleen but after experimental
autoimmune encephalomyelitis (EAE) induction in the mouse, LCN2 was
significantly increased in the spleen, specifically in the neutrophils and dendritic cells
(Nam et al., 2014).
1.6.2.12 Synovial fluid
LCN2 is highly expressed in the synovial fluid of patients with rheumatoid
diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA) (Gupta et al., 2007;
Katano et al., 2009) compared to healthy control. However, synovial LCN2 levels were
approximately 15 times higher than in plasma. Moreover, neutrophil LCN2 is
positively correlated with granulocyte cells detected in the synovial fluid (Bläser et al.,
1995) and LCN2 detected in OA synovial fluid up regulates cartilage breakdown by
protecting MMP‐9 against auto‐degradation (Gupta et al., 2007), which supported and
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suggested LCN2 as a biomarker for arthritic disease and inflammatory disorders
(Wilson et al., 2008).
The below Table 1 summarizes the tissue distribution of LCN2 under various
pathological conditions.
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Table 1: Tissue distribution of altered lipocalin-2 expression in human, rat and
mouse in organ disorders.
Tissue/cell

Type of
lipocalin-2

Species

Method of
localization

Authors

LCN2 protein

Mouse/human

qRT-PCR, WB, IHC

(El Karoui et al.,
2016)

LCN2 mRNA
LCN2 protein
Kidney

ELISA, qRT-PCR
Mouse

ELISA

LCN2 mRNA
LCN2 protein

Human

(Belcher et al.,
2014)

LCN2 mRNA
LCN2 protein

Mouse

qRTPCR, WB

LCN2 mRNA

Mouse

RT-PCR, WB

(Aigner et al.,
2007)

LCN2 protein

Human

qRT-PCR, ELISA,
WB

(Zhao et al.,
2016)

Mouse/human

IF, IHC, ELISA,
qRT-PCR

(Marques et al.,
2012)

Mouse

ELISA

(Slater et al.,
2013)

Human

ELISA

Mouse

ELISA

LCN2 mRNA

Human

IHC,ELISA,NB

LCN2 mRNA

Human

qRT-PCR

LCN2 protein

Human

WB, Zymographic
analysis

(Gupta et al.,
2007)

ELISA

(Bläser et al.,
1995)

Human

IHC, RT-PCR

(Mallbris et al.,
2002)

Human/mouse

RTPCR,ELISA,WB,

LCN2 mRNA
Heart

LCN2 protein

LCN2 mRNA
Brain

LCN2 protien

LCN2 protein
LCN2 protein
Pancreas
LCN2 protien

Lung

Synovial fluid

LCN2 protein
Human
Skin

(Ashraf et al.,
2016)

LCN2 protein
LCN2 mRNA
LCN2 protein
LCN2 mRNA

IHC, Cell culture,
Chemotaxis assay

(Xiong et al.,
2016)

(Kaur et al.,
2013)
(Chakraborty et
al., 2010)
(Cowland et al.,
2003)
(Kangelaris et
al., 2015)

(Shao et al.,
2016)
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1.6.3 Inductors of Lipocalin-2 Expression
1.6.3.1 Proinflammatory Cytokines
1.6.3.1.1 Tumor Necrosis Factor Alpha (TNFα)
Several studies have shown that TNFα induces the expression and secretion of
Lcn2 (Yan et al., 2007; Lin et al., 2001). The continuous treatment of 3T3-L1
adipocytes by TNFα for 24, 48, or 72 h have shown marked increase in LCN2
expression and secretion within 24 h, when compared to control. However, the effect
of TNFα on LCN2 levels increased over time. The ability of TNFα to induce Lcn2
mRNA expression is dependent on NF-κB pathway. siRNA-mediated knockdown of
P65 subunit of NF-κB has significantly attenuated the induction of TNFα on LCN2
expression and secretion (Zhao et al., 2014). Lee et al. also confirmed that treatment
of primary astrocytes with by TNFα (100 ng/ml) significantly increased the expression
of LCN2 (Lee et al., 2009).
1.6.3.1.2 Interferon γ (IFNγ)
Several studies have shown that IFNγ induce LCN2 expression and secretion
in cultured murine and human adipocytes. Intraperitoneal injection of IFNγ have been
shown to stimulate Lcn2 expression and secretion in mice epididymal WAT. Post 24 h
treatment by IFNγ, the cellular levels of LCN2 were induced and remained high. The
ability of IFNγ to induce Lcn2 mRNA expression is dependent on STAT1 pathway.
siRNA-mediated knockdown of STAT1 has resulted in marked attenuation in the
induction effect of IFNγ on LCN2 expression and secretion (Zhao et al., 2014).
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1.6.3.1.3 Lipopolysaccharides (LPS)
Lipopolysaccharide is a strong inducer for lipocalin-2 expression in different
tissues. The administration of peripheral LPS in mice for 24 h resulted in high
detection of lipocalin-2 inducement by LPS with over a 140-fold induction. However,
LCN2 was not detected in Lcn2−/− mice, treated with Phosphate buffered saline (Kang
et al., 2018). Another study investigating reactive astrocytosis has also confirmed that
treatment with by LPS (100 ng/ml) markedly increased the expression of LCN2 (Lee
et al., 2009).
1.6.3.1.4 17-β-Estradiol (E2)
Treatment of subcutaneous adipose tissue from postmenopausal women with
17-β-estradiol (E2) resulted in significant increase in LCN2 gene expression by 4-fold
and LCN2 protein expression by 2.7-fold. E2 eﬀects on LCN2 is suggested to be
regulated by ERβ pathway but not through ERα pathway. It has been identified that
dexamethasone+E2 can mediate LCN2 expression by the inhibition of ERα and
stimulation of ERβ suggesting it may result and play a role in the development of
glucocorticoid-induced insulin resistance in human adipose tissue (Kamble et al.,
2019).
1.6.3.1.5 Hyperglycemia
Lipocalin-2 expression is increased in diabetic/obese mice in various tissues as
adipose and liver tissue. The use of microarray analysis for identification of genes
expressed in db/db obese/diabetic mice and controls resulted in the expression of
lipocalin-2 gene. This was significantly induced in the liver tissue of obese/diabetic
mice, as well as human subjects with diabetes, where they showed higher mean serum
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concentrations of lipocalin-2 than those who were not affected by the disease (Wang
et al., 2007).
1.6.3.1.6 Gender
The measurement of lipocalin-2 concentrations in serum samples collected
from 229 adult participants by Wang et al. has revealed that lipocalin-2 concentrations
in obese and lean groups were markedly higher in males compared to females. They
showed that circulating lipocalin-2 concentrations in smokers were much higher than
those in nonsmokers (Wang et al., 2007). Another study has also demonstrated that in
adipose tissue, men had higher LCN2 mRNA expression than women (Kamble et al.,
2019).
1.6.3.1.7 Obesity
There is a positive correlation between serum lipocalin-2 concentrations and
BMI (Wang et al., 2007). Western blot analysis, immunoprecipitation and in-house
immunoassay measuring human lipocalin-2 showed that the affinity of lipocalin-2
antibody selectively were attracted to an ∼25-kDa protein, which was confirmed by
tandem mass spectrometry analysis to be human lipocalin-2, which demonstrated that

lipocalin-2 concentration in obese subjects was markedly higher than those in lean
ones. Moreover, the plasma concentration of lipocalin-2 were higher in obese than lean
subjects in both human and murine (Wang et al., 2007). Another study has also
revealed a signiﬁcant upregulation of LCN2 expression and secretion in adipose tissue
of obese (ob/ob) mice compared to lean controls (Yan et al., 2007).
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1.6.3.1.8 Advanced Glycation End-Products (AGEs)
AGE treatment increases the mRNA and protein expression of LCN2. AGE
stimulates LCN2 expression via RAGE-NADPH oxidase reactive oxygen species
pathway, by the activation of PI3K-Akt and JNK signal transduction in human aortic
smooth muscle cells (HASMCs). The activation of C/EBPβ is responsible for the
transcriptional activation of LCN2 expression induced by AGE (Chung et al., 2013).
1.6.3.1.9 Insulin
In human omental adipose tissue explants, continuous infusion of insulin
showed a significant dose-dependent increase in LCN2 expression and secretion.
Insulin can also stimulate the expression of LCN2 via PI3K and MAPK signaling
pathways (Tan et al., 2009).
1.6.3.1.10 Dexamethasone
Dexamethasone is a synthetic analog of glucocorticoid. It is a strong inducer
of LCN2 expression and secretion. Treatment of 3T3-L1 adipocytes with
dexamethasone resulted in the induction of Lcn2 mRNA by ∼80-fold. Furthermore, a
mixture of methylisobutylxanthine and dexamethasone had a significant effect on

LCN2 expression. However, dexamethasone was the dominant contributor to LCN2
induction (Yan et al., 2007).
1.6.3.1.11 BAY16
The treatment of male wistar rats with BAY16 a hepatotoxic agent has resulted
in upregulation of LCN2 mRNA levels after 24 hours of treatment which continuously
increased by ~16-fold and 37-fold after 3 days and 12 days following repeated
administrations of BAY16. LCN2 serum levels correlated with the severity of liver
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injury. Increased expression of LCN2 was detected in hepatocytes, biliary epithelial
cells and proximal tubular epithelial cells of the kidney (Adler et al., 2010).
1.6.3.1.12 NF-κB Signaling Pathway
LCN2 contains the binding site of NF-κB in its promoter region. The nuclear
factor-κB (NF-κB) is a transcription factor that mediate key pathways. Originally NFκB signaling pathway was identified in immune cells and has emerged as a key
mediator of LCN2 gene expression. NF-κB is comprised of five transcription factors
p50, p52, p65 (RelA), c-Rel and RelB. the N-terminal region of these proteins
establishes a common domain, Rel homology domain (RHD), which is important for
the NF-κB dimerization and DNA binding activity. The C-terminal region of RelA
(p65), c-Rel and RelB have transcription activation domain (TAD) therefore they
activate gene expression, whereby p50 and p52 have a transcription repression domain
(TRD) which inhibits gene expression. p50 and p52 require coactivators to be
associated with in order to induce gene expression. NF-κB proteins bind to a specific
sequence in the promoter region of target genes where they activate or inhibit gene
expression depending on the presence of TAD or TRD. In case of LCN2 which is
positively regulated by agents that influence the signaling pathway of NF-κB as TNFα,
IL-1β and LPS, which are potent inducers of insulin resistance. In normal state IκB
blocks the activity of NF-κB by binding to it. Due to the influence of NF-κB signaling,
IκB kinase (IKK) becomes activated this kinase phosphorylate the inhibitor of NF-κB
(IκB) resulting in the dissociation of IκB from NF-κB, and IκB is then ubiquitinated
and degraded by proteasome. The free NF-κB translocate to the nucleus and regulates
the expression of target genes (Hayden & Ghosh, 2008) as shown in Figure 2.
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Figure 2: Regulation of LCN2 expression by NF-κB. NF-κB is present in the cytosol
as heterodimer (Rel-A and p50) but it is kept inactive by the inhibitor of NF-κB
(IκB). When the signaling molecule binds to the specific receptor that is present in
the cell membrane, the receptor becomes activated and it phosphorylate IKK, which
in turn phosphorylates IκB. The phosphorylated IκB gets ubiquitylated followed by
subsequent degradation by proteasome, freeing the NF-κB complex, which
translocates to the nucleus and binds with other coactivators and RNA polymerase.
The complex in turn binds to the κB response element (κB RE) located at position
−181/−171 on the LCN2 promoter. This leads to activation of transcription of LCN2
gene. Abbreviations: NF-κB, nuclear factor kappa B; IKK, IκB kinase; IκBα, nuclear
factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha.

1.6.3.14 ERK Signaling Pathway
Extracellular signal-regulated kinase (ERK) is a member of the mitogen
activated protein kinases (MAPKs) family. ERKs have a key role in regulating cell
proliferation, cell growth and cell division. ERK signaling pathway begins with the
binding of a ligand such as EGF to the extracellular portion of the membrane bound
receptor of the family of receptor tyrosine kinase (RTK). EGF binding leads to the
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dimerization of two subunit of the receptor tyrosine kinase, which catalyzes
phosphorylation. The Grb2 binds to the phosphorylated RTK, then SOS binds to the
Grb2. SOS activates Ras by substituting the GDP by GTP, while the activated Ras
induces the activation of B-Raf. The activated Raf phosphorylates and activates
MEK1/2, then, activated MEK1/2 phosphorylate and activate ERK1/2. ERKs are
serine/threonine kinases. The kinase cascade leads to the activation of (jun) and (fos)
transcription factors of the activator protein-1 (AP-1) family. Upon activation, these
transcription factors translocate to the nucleus and bind to AP-1 motif of the DNA
which leads to the expression of many genes encoding growth factors, cyclins and
cytokines (Kim & Choi, 2010) as shown in Figure 3. A study by Zhao et al. have
demonstrated that ERK signaling pathway regulates the capability of IFNγ and TNFα
to induce LCN2 expression without effecting the nuclear translocation or DNA
binding activity of STAT1 and NF-κB by IFNγ and TNFα. This suggests that ERK
signaling pathway is vital for the maximum transcriptional activity of STAT1 and NFκB (Zhao & Stephens, 2013b). Another study suggested that TNFα induces insulin
resistance in 3T3-L1 adipocytes through suppressing the phosphorylation and
expression of IR, IRS1/2 via the ERK signaling pathway (Fujishiro et al., 2003). A
different study showed that the activation of the ERKs signaling pathway stimulates
adipogenesis via regulating the gene expression of PPARγ and C/EBPα. These
elements are critical for adipogenesis (Prusty et al., 2002). Treatment of murine 3T3L1 adipocytes with IFNγ resulted in the degradation of PPARγ in adipocytes by IFNγinduced ERKs activation which mediates phosphorylation of PPARγ at Serine112
(Floyd & Stephens, 2002).
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Figure 3: Regulation of LCN2 expression by ERK signaling pathway. Once EGF
binds to the EGFR it gets activated and phosphorylated then it attaches to the Grb2
and Sos proteins in the cytosolic section. Grb2 and Sos activates Ras by substituting
the GDP of Ras by GTP. Ras directly interacts with B-Raf and activates it. Raf then
phosphorylates and activates MEK, which in turn phosphorylates and activates
ERKs. ERKs lead to the activation of the transcription factors c-jun and c-fos.

1.6.3.1.15 JAK-STAT Signaling Pathway
The Janus kinase (JAK)-signal transducers and activators of transcription
(STAT) signaling pathway is used by hormone and cytokine receptors. It has been
demonstrated that it up-regulates the expression of LCN2. There are four members of
the JAK family: Jak1, Jak2, Jak3 and Tyk2, each of these contain a SH2 domain and
FERM (four-point-one, ezrin, radixin, moesin) domain. and seven members of the
STAT family: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6.
However, only STAT1, 3, 5A, 5B and 6 are expressed in mature adipocytes (Zhao &
Stephens, 2013a). The pathway operates by activation of the receptor by the ligand
(GM-CSF), the Tins as (EPO, Prolactin, Thrombopoetin and Leptin) and the Ters,
which include interleukins and interferon. Activated JAK binds to the receptor and
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phosphorylates the receptor on tyrosine residues. In the unstimulated cell, STAT is
inactivated, while the activated JAK causes the recruitment of STAT and
phosphorylates it. The phosphorylated STAT binds to another STAT and form
homodimer or heterodimer with other STAT isoforms. STATs homodimer translocate
to the nucleus and interact with promoters to modulate gene expression (Darnell, 1997)
as illustrated in Figure 4. Previous studies have illustrated activators of JAK-STAT
signaling pathways including cytokines IL-1 and IL-17 (Florin et al., 2004; Yang et
al., 2008), Gp130 cytokines, including cardiotrophin-1 (Zvonic et al., 2004), IFNγ
(Hogan & Stephens, 2003), interleukin-11 (Tenney et al., 2005) have been identified
to utilize STAT1 and STAT3 signaling pathways in adipose cells. A cross talk between
the JNK and NF-κB has been also suggested to act together to influence LCN2
expression.
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Figure 4: Regulation of LCN2 expression by JAK-STAT signaling pathway. The
receptor gets activated by the binding of the specific ligand and activated JAK binds
to the receptor and phosphorylates its own tyrosine component to activate its kinase
function, which in turn phosphorylates STAT. Phosphorylated STAT binds to
another STAT and forms a homodimer or heterodimer and then translocate to
promote DNA transcription in the nucleus. Abbreviations: JAK, janus kinase; STAT,
signal transducer and activator of transcription.

1.6.4 Inhibitor of Lipocalin-2 Expression
1.6.4.1 Rosiglitazone
Rosiglitazone is a drug with insulin-sensitizing and anti-inflammatory
activities. The serum samples of T2DM patients treated with the peroxisome
proliferator–activated receptor-γ agonist rosiglitazone, showed a significant decrease
in circulating concentrations of lipocalin-2, and a marked decrease also has been
detected in LCN2 expression in mice and circulating concentrations in both murine
and humans. Moreover, rosiglitazone-mediated relative changes in serum lipocalin-2
concentrations correlated well with relative changes in insulin sensitivity and Creactive protein (Yan et al., 2007; Wang et al., 2007).
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1.6.5 Controversial Factors in LCN2 Expression
1.6.5.1 Epidermal Growth Factor (EGF)
Treatment of PDAC cell line AsPC-1 and BxPC-3 with EGF decreased the
expression of LCN2 mRNA (by 48.4% in AsPC-1 and 44.7% in BxPC-3 cells)
compared with untreated cells as detected by Q-PCR. Moreover, LCN2 protein was
also markedly reduced by EGF treatment as detected by both Western blot analysis
and immunofluorescence. This was accompanied with a marked decrease in the
epithelial marker E-cadherin. EGF decreased LCN2 expression through the inhibition
of the NF-κB pathway. However, in other cell types EGF showed different effect on
LCN2 expression for example in renal tubular epithelial cells a treatment with EGF
has resulted in upregulation of LCN2 expression via stabilization of HIF-1α (hypoxia
inducible factor-1 α).
1.6.6 Lipocalin-2, Obesity and Insulin Resistance
LCN2 is a critical adipocytokine in the regulation of energy metabolism,
glucose and lipid metabolism, body fat mass and insulin resistance. It has a regulatory
importance in the activation of PPARγ, which mediates adipogenesis and lipogeneses
in liver and adipose tissue (Zhang et al., 2008). However, the clear mechanism of
LCN2 in the pathogenesis of obesity-related diseases is not clear yet. Both the mRNA
expression and serum levels of LCN2 in adipose tissue and liver are markedly
increased in obese and diabetic murine as well as in mice fed high fat diet (HFD) (Guo
et al., 2010). Circulating LCN2 concentrations positively correlate with measures of
adiposity, hyperglycemia, hypertriglyceridemia, and the insulin resistance index in
humans (Wang et al., 2007). In obesity and related disorders, LCN2 expression and
secretion is stimulated by proinflammatory cytokines as IL-6, IL-B, IFNγ and TNFα
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in cultured human and mice adipose cells. Zhao et al. has demonstrated that IFNγ
induces the expression of LCN2 via activating STAT1 and TNFα needs NF-kB
signaling pathway in order to mediate LCN2 expression and secretion. This
mechanism occurs in both human and murine (Zhao et al., 2014). LCN2 promoter
contains the binding site of key transcription factors CCAAT/enhancer binding protein
(C/EBP) and NF-kB (Shen et al., 2006) demonstrating that the transcriptional
activation of LCN2 gene in the adipose tissue has a role in obesity, inflammation and
metabolic disorders. In both preclinical and clinical research, a role for LCN2 has been
demonstrated in obesity, insulin resistance and diabetes (Moreno-Navarrete et al.,
2010; Wang et al., 2007; Yan et al., 2007). Recent studies suggest that LCN2 increases
insulin resistance as law and colleagues showed that LCN2 knockout mice were
protected from HFD-induced insulin resistance this effect was accompanied by
attenuation in the expression of TNFα and 12-lipoxygenase in the tissues of the LCN2
deficient mice (Law et al., 2010). Another study showed that insulin sensitivity and
glucose metabolism has been improved in LCN2 deficient cultured adipocytes(Yan et
al., 2007). A preclinical study showed that a knockdown of LCN2 in mice resulted in
increase in hepatic gluconeogenesis, decreased mitochondrial oxidative capacity,
impaired lipid metabolism, and elevated inflammatory state under the high fiber diet
condition in different organs. LCN2 deficient mice has showed an increase in insulin
resistance, dyslipidemia, and fatty liver disease (Guo et al., 2010). Human study by
(Huang et al., 2012) has showed that circulating levels of LCN2 was markedly higher
in subjects with isolated impaired fasting glucose, isolated impaired glucose tolerance,
combined impaired fasting glucose/impaired glucose tolerance and recently-diagnosed
type 2 diabetes than normal subjects. This result suggests that LCN2 upregulation is
in association with a higher risk for impaired glucose regulation and type 2 diabetes.
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Insulin induction in human markedly increased serum LCN2 levels and its secretion
in omental adipose tissue. This was modulated by phosphatidylinositol 3-kinase and
mitogen-activated protein kinase (Tan et al., 2009). Another study conducted by (Liu
et al., 2011) resulted in no correlation between cardiovascular risk factors and
circulating levels of LCN2 and homeostasis model assessment of insulin resistance.
Although some observations suggest a potentially metabolically protective role of
LCN2, there are substantial inconsistent observations related to actions of LCN2 in
relation to glucose tolerance and insulin sensitivity
1.6.7 LCN2 Gene and Diabetes
The cDNA sequence of human Lipocalin 2 is related to human chromosome 9
with a cytogenetic map 9q34.11. The promoter region of the Lcn2 gene contains the
binding sites of several transcription factors, and nuclear receptor response elements,
including nuclear factor-κB (NF-κB) (Shen et al., 2006; Zhao & Stephens, 2013b);
CCAAT-enhancer binding protein (C/EBP) (Shen et al., 2006); glucocorticoid
response element (Garay-rojas et al., 1996); retinoic acid response element (Shen et
al., 2006; Guo et al., 2016); estrogen response element (Seth, al., 2002), and STAT1
(Zhao & Stephens, 2013b). All of this information indicates that the expression of
LCN2 is important in diabetes and obesity, which represent the state of metabolic
inflammation. Studies by different groups have indicated that diabetes which is
accompanied by mild chronic subclinical inflammatory condition results in elevated
levels of LCN2 in serum and different tissues (Bhusal et al., 2019; Lin et al., 2001).
Induction of type 1 diabetes by streptozotocin in murine have shown increased levels
of LCN2 in multiple tissues. In several studies, diabetic induced animals via
streptozotocin injection resulted in elevation of LCN2 in body fluids as urine and

38
different body tissues as the kidney where it is usually used as a biomarker for acute
and chronic kidney injury (Arellano-buendía et al., 2014; Brouwers et al., 2014;
Korrapati et al., 2012; Liu et al., 2015). In a study conducted by (Soukas et al., 2000),
upregulation of LCN2 was observed in the white adipose tissue of obese mice suffering
from severe type 2 diabetes when compared with lean controls. Moreover, LCN2
expression is elevated in several murine obese and diabetic models as well as people
(Yan et al., 2007; Eun et al., 2018; Tak et al., 2016; Kanaka-gantenbein et al., 2008).
In addition, fatty liver disease human and murine models samples revealed elevation
in LCN2 and its key association in lipid metabolism, inflammation and insulin
resistance (Lambertz et al., 2017; Ye et al., 2016; Asimakopoulou et al., 2014; Semba
et al., 2013).
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Chapter 2: Aims, Hypothesis and Objectives
2.1 Hypothesis
The administration of lipocalin 2 would improve the metabolic complications
of diabetes mellitus and enhance insulin secretion from the islet of Langerhans of
diabetic rats.
2.2 Aim
To examine the effect of lipocalin 2 in the management of euglycemia,
improving the secretion of insulin from β-cells of the pancreas and reducing oxidative
stress in STZ-induced diabetic rat.
2.3 Objectives
1.

Examine the effect of lipocalin 2 on total body weight and fasting blood glucose.

2.

Determine how lipocalin 2 treatment would influence biochemical parameters,
especially biomarkers of hepatic and renal functions.

3.

Study the expression of lipocalin 2 in endocrine pancreas of normal and diabetic
rats.

4.

Determine whether lipocalin 2 co-localizes with endocrine hormones in the islet
of Langerhans

5.

To investigate how lipocalin 2 affects insulin release from normal and diabetic
rat pancreas

6.

Determine whether lipocalin 2 mitigate diabetes-induced oxidative stress in the
pancreas and liver of diabetic rats
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7.

To examine the effect of lipocalin 2 treatment on molecules involved in insulin
signaling.
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Chapter 3: Materials and Methods
3.1 Animal Model
Three months of age male Wistar rats weighting approximately 250 g were
utilized in this study. All animals were provided by the Animal Facility in the College
of Medicine and Health Sciences, United Arab Emirates University. Animals were
kept under specific pathogen free environment and maintained at 22-25°C with 12
hours light/dark cycle. They were housed in polycarbonate cages containing wood
chips bedding in groups of three animals per cage. Cages were replaced every two days
for the diabetic animals and twice weekly for normal animals. Animals were fed a
standard rat chow diet and supplied with tap water ad libitum. The study was approved
by Institutional Ethical Committee of the United Arab Emirates University, Al Ain,
UAE (A5-14).
3.2 Establishing the Experimental Diabetes Model
The diabetic animal model was established by intraperitoneally injecting male
wistar rats with a single dose of streptozotocin (STZ) using a dose of 60 mg/kg body
weight. Streptozotocin were prepared freshly on the day of injection by dissolving it
in citrate buffer (pH 4.5, 0.5 M) and was kept on ice at the time of injections. After 7
days, animals were fasted for 8 hours before checking FPG levels and only animals
with readings > 250 mg/dl were considered diabetic. Animals with readings below 250
mg/dl were considered not diabetic and excluded from the study to maintain a standard
of STZ-induced diabetes mellitus with a single dose.
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3.3 Experimental Design
Animals were primarily divided into two groups, normal and diabetic. After
that a further division were performed in each group into two sub-groups. One was
injected with normal saline and the other with 8 μg/Kg of lipocalin-2 five-days/week
for a period of 2 weeks.

Figure 5: Schematic diagram of the animal groups in the study.

During the treatment period the animals body weight were checked once a
week and their blood glucose levels were assessed from the tail vein using OneTouch®
Ultra® glucometer (LifeScan, Inc., Milpitas, CA, USA) after fasting them for 8 hours.
At the end of the treatment period of 2 weeks, intraperitoneal glucose tolerance test
(IPGTT) was performed for all groups after 12 hours of fasting. Rats were injected
with a glucose with the dose of 10 mg/kg intraperitoneally and blood samples were
obtained from the tail vein at different time points 0, 30, 60, 90, and 120 minutes.
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3.4 Blood/Tissue Collection and Tissue Processing
Prior to tissue collection IPGTT were performed, the animals then were
anesthetized using a ketamine and xylazine cocktail (Albert Einstein Institute for
Animal Studies, 2015). An incision was made through the abdominal wall. The blood
was collected from the inferior vena cava using a 5-ml syringe. The pancreas was
isolated and separated into three samples for immunohistochemistry (IHC), electron
microscopy (EM), and molecular biology investigation. The liver was isolated for
molecular biology investigation, and lastly, the gastrocnemius muscle was isolated for
molecular biology investigation. The samples for the immunohistochemistry analysis
were washed with PBS and embedded in Zamboni fixative, samples for electron
microscopy (EM) analysis were washed and embedded in McDowell fixative and the
samples for molecular biology analysis (WB) were snap frozen by liquid nitrogen then
stored at -80oC.
After one week of fixing the tissues, they were processed for further analysis.
Samples that have been fixed in Zamboni for IHC, have been processed to make
paraffin blocks by dehydrating the tissues through a series of ascending ethanol
concentrations from 70% to 95% followed by two rounds in absolute ethanol. Then
the tissues were dipped in xylene I and II for 2 hours each followed by three rounds in
paraffin wax at 55°C. Then the tissues were embedded in paraffin blocks and
transferred to the freezer to cool down and solidify. Tissues blocks were removed,
trimmed, and sectioned into 3-5 μm thickness using a microtome. Sections were placed
in a water bath with a temperature of 42°C, and later transferred onto coated slides.
Slides were kept overnight to dry and for the sections to attach properly. Tissue
samples kept in McDowell fixative for EM were cut into small pieces. Fat and
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connective tissues were removed, then washed three times with 0.1 phosphate buffer
each for 20 minutes. After that, tissues were incubated in 1% osmium tetroxide for 60
minutes followed with a dehydration step by immersing the tissues in a series of
ascending concentrations of ethanol (30%, 50%, 70%, 95% and two changes of 100%)
20 minutes each. Tissues were then incubated at a ratio of 1:1 of LR White resin and
95% ethanol for one hour at room temperature on a rotator. Tissues were then
infiltrated with pure LR White resin overnight at 4°C. On next day morning, samples
were incubated with 100% fresh LR White for two hours at room temperature,
specimens were embedded in pure resin in gelatin capsules. For polymerization gelatin
capsules were placed in a holder under UV lamp (360-365 nm) in a chamber for 2436 hours at room temperature. Resin blocks were removed from the gelatin capsules,
and trimmed to expose the surface of the tissue for sectioning. Ultra-thin sections were
obtained using diamond knife and they were put on nickel grids, which were placed
on a filter paper to dry up.
3.5 Immunofluorescence Staining of Paraffin Sections
After generating tissue sections slides, sections were processed for
immunohistochemical analysis. First dewaxing of the sections was achieved by
immersing the slides by 2 washes with xylene each 5 minutes followed by rehydrating
step achieved by incubating the slides for 3 minutes each in a series of descending
concentrations of ethanol (two changes of 100%, 95%, 75%, and 50%). Then slides
were kept in distilled water for 5 minutes and then they were transferred to a container
with citrate buffer and placed in microwave for antigen retrieval. Slides have been
cooled down for 20 minutes followed by 3 washes with PBS 5 minutes each. After that
sections were marked with Pap-pen to determine the area of interest upon adding
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antibodies. Blocking buffer then were added to the tissue sections for 45 minutes at
room temperature to avoid any unspecific binding. After that, the primary antibody
(Table 2 below) is added to the sections and left overnight at 4°C. The primary
antibodies added were, insulin anti-guinea pig, lipocalin-2 anti-mouse, glucagon antirabbit, superoxide dismutase anti-rabbit, catalase anti-rabbit and glutathione reductase
anti rabbit. On the next day, slides were washed with PBS for 3 times each for 5
minutes and then the secondary antibody was added and incubated for 1 hour at room
temperature (FITC-guinea pig, Rhodamine-rabbit/mouse and FITC- rabbit). Finally,
slides were washed three times with PBS, 5 minutes long each and then a mounting
medium was added to the tissue sections (DakoCytomation Fluorescent mounting
medium). Using fluorescence microscope and AxioCam HRc digital camera with
AxioVision 3.0 software (Carl Zeiss, Oberkochen, Germany) fixed with z-place
fluorescence, sections were investigated, and pictures were collected and adjusted
using image J 1.47V.
Table 2: Primary and secondary antibodies used in IHC and their dilutions.
Primary
antibody

Dilution

Source

Secondary antibody

Dilution

Source

Lipocalin-2
Mouse

1:100

Abcam

Rhodamine-Mouse

1:100

Jackson
ImmunoResearch

Insulin
Pig

1:2000

Dako

FITC-Guinea Pig

1:100

Jackson
ImmunoResearch

Glucagon Rabbit

1:500

Dako

FITC- rabbit

1:100

Jackson
ImmunoResearch

Superoxide
dismutase
Rabbit

1:500

Rockland

Rhodamine-Rabbit

1:100

Jackson
ImmunoResearch

Catalase Rabbit

1:500

Abcam

Rhodamine-Rabbit

1:100

Jackson
ImmunoResearch

Glutathione
reductase Rabbit

1:500

Abcam

Rhodamine-Rabbit

1:100

Jackson
ImmunoResearch

Guinea
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3.6 Immunoelectron Microscopy
Grids containing pancreatic sections were jet washed with deionized water then
the grids were incubated with 10% H2O2 in water for 10 minutes. Followed by a wash
with deionized water and then the grids containing pancreas sections were immersed
for 20 minutes in 0.5 M NH4Cl in 0.01 M PBS (pH7.3). After that the grids were
washed with washing buffer for 5 minutes then the tissues were blocked with washing
buffer containing 20% normal goat serum (NGS) then the primary antibody (mouse
anti-lipocalin-2) was added and incubated overnight at 4°C. On the next day, grids
were kept at room temperature for an hour, washed with PBS for 3 times and incubated
with blocking buffer for 20 minutes at room temperature. After that, secondary
antibody (goat anti-mouse IgG coated with 10 nm gold particles) was added and
incubated for 2 hours at room temperature. Grids were washed again with PBS for 3
times and the above steps were repeated for the same grids using a different primary
antibody (rabbit anti-insulin) and incubated at room temperature for 2 hours. Grids
were incubated in goat anti-rabbit IgG coated with 15 nm gold particles on the next
day and grids were then fixed with glutaraldehyde (2.5% aqueous) for 5 minutes,
washed with deionized water and allowed to dry overnight on a filter paper. On the
following day, using uranyl acetate for 15 minutes and lead citrate for 7 minutes, grids
were contrasted followed by a last wash with deionized water before viewing them
with Philips TEM.
3.7 Markers of Oxidative Stress
Different oxidative stress markers were analysed including glutathione
reductase (GSH), superoxide dismutase (SOD) and catalase levels in serum using
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colorimetric analysis and in pancreas tissue using double-labeling immunofluorescence
technique.

To measure glutathione reductase activity in serum, 25 µL of the serum was
taken and 25 µL of 5% sulphosalicylic acid was added (1:1) ratio for deproteinization
and to clear the turbidity of the serum. Next, serum in sulphosalicylic acid were
centrifuged at 10000 rpm for 10 minutes at 4°C and the supernatant was transferred
into a multi-well dish for colorimetric analysis. However, for Serum levels of SOD the
serum was directly used in the colorimetric analysis using Cayman Chemical SOD
assay kit (Cayman Chemical, Ann Arbor, Michigan, USA).
3.8 Biochemical and Peptide Hormone Analysis
3.8.1 Biochemical Analysis Using Cobas®
Biochemical analyzer was utilized to obtain clinical chemistry profiles using
rat serum. Various markers have been investigated and quantified including lipid
profile markers triglycerides (TG), cholesterol (CHOL), low density lipoprotein
(LDL), high density lipoprotein (HDL), Kidney function markers such as, creatinine,
urea, blood urea nitrogen (BUN), and liver function markers such as aspartate
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase
(ALP), albumin (ALB) total protein and bilirubin.
3.8.2 Peptide Hormone Analysis Using Magpix®
The Magpix® Platform is a fluorescent-based detection system that can detect
various biological molecules, such as proteins and nucleic acids, from the same
sample. This technology depends on microspheric colourful beads that are coupled to
reagents that can bind to the target analytes. Beads are added to a 96-well plate and
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mixed with the sample being tested, beads will bind to the analyte based on antibodyprotein reaction, the complex is biotinylated and finally the detection molecule is
attached.
3.9 Cell culture, Treatment, and Insulin Secretion
INS-1 832/3 rat insulinoma cell line (obtained from Millipore #SCC208) were
maintained in complete RPMI-1640 (Sigma Cat. No R0883) media supplemented with
2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 0.05 mM βmercaptoethanol and 10% fatal bovine serum cultured at 37°C in a 5% CO2
atmosphere. For glucose stimulated insulin secretion, cells were incubated in HBSS
containing 114 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/LKh2PO4, 1.16 mmol/L
CaCl2. 25.5 mmol/L NaHCO3, and 0.2% bovine serum albumin, pH 7.2. then cells
were washed with HBSS + 2.5 mM glucose. After wash, cells were incubated for 1 h
in HBSS with 2.5 mM glucose for basal insulin secretion and HBSS with 15 mM
glucose for stimulated insulin secretion. After one hour, lipocalin-2 peptide was added
to respective wells at 10-8 M, 10-10 M and 10-12 M and a control well was maintained
with no peptide for 2 hours. After 2 hours the supernatant was removed to determine
the insulin content using Mercodia high range rat insulin ELISA kit (Mercodia,
Sylveniusgatan 8A, Uppsala, Sweden).
3.10 SDS-PAGE and Western Blot Analysis
Cell lysates were prepared using RIPA buffer containing Pierce Protease
inhibitor mini tablets. Equal amounts of cellular protein extracts or supernatants were
diluted with LDS containing 10% mercaptoethanol as reducing agent, heated at 95°C
for 5 minutes, and separated in 10% or 8% gels, using TGS running buffers. Proteins
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were transferred into 0.2 μm Pvdf membranes (Thermo Scientific, Germany) and equal
loading was shown in Ponceau S stain. Non-specific binding sites were blocked in
Tris-buffered saline (TBS) containing Tween 20 and 3% non-fat milk powder.
Appropriate primary antibodies (Table 3) were diluted in 3% blocking buffer (non-fat
milk powder in TBST). And they were visualized by probing the membrane with the
corresponding horseradish peroxidase conjugated anti-mouse or anti-rabbit IgG (BIORAD, USA) and the reactive bands were visualized using ECL plus substrate (Thermo
scientific, USA).
Table 3: Primary and secondary antibodies used in WB analysis and their dilutions.
Primary
antibody

Dilution

Source

Secondary
antibody

Dilution

Source

GAPDH

1:5000

Cell
signaling

horseradish
peroxidase
conjugated antirabbit IgG

1:20,000

BIO-RAD

AKT

1:1,000

Cell
signaling

horseradish
peroxidase
conjugated antirabbit IgG

1:20,000

BIO-RAD

p-AKT

1:1,000

Cell
signaling

horseradish
peroxidase
conjugated antirabbit IgG

1:20,000

BIO-RAD

PI3K

1:1,000

Abcam

horseradish
peroxidase
conjugated antimouse IgG

1:20,000

BIO-RAD

LCN2

1:1,000

Abcam

horseradish
peroxidase
conjugated antimouse IgG

1:20,000

BIO-RAD

3.11 Statistical Analysis
Data samples were expressed as mean ± standard error of the mean. Statistical
differences were analyzed using one-way ANOVA test on GraphPad software and the
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p-value were obtained using tukey karmer post hoc test (GraphPad Software, San
Diego, CA, USA). Values for differences with p < 0.05 were considered significant.

51

Chapter 4: Results
4.1 Metabolic Parameters
The below Figures (6) and (7) show the time courses of changes in body weight
(g) and blood glucose level (mg/dl) in LCN2-treated (8 μg/Kg) and untreated diabetic
and age-matched control rats over the 3 weeks period of the study. The presented
results show that untreated diabetic rats suffered from significant weight loss when
compared with age-matched normal controls. STZ-induced diabetic rats treated with
LCN2 showed significant increase in body weight in comparison with saline-treated
diabetic group. Moreover, diabetic rats had significantly elevated blood glucose levels
compared with non-diabetic rats. LCN2 treatment of diabetic rats caused a slight
improvement in glucose levels after one week and two weeks when compared with the
diabetic control rats however, no significant reduction were observed.

4.1.1 Body Weight

Figure 6: Effects of LCN2 treatment on weight in normal and diabetic animals. Note
significant differences in body weight between DMUT and DMT. Values represented
as mean ± SEM, n=6
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4.1.2 Glucose Level

Figure 7: Effects of LCN2 on fasting plasma glucose levels in normal and diabetic
animals. Values represented as mean ± SEM, n=6 Time course graphs representing
the effect of LCN2 treatment on (a) body weight and (b) blood glucose levels in
normal saline-administered, normal LCN2-administered, saline-administered diabetic
and LCN2-administered diabetic rats. Values represented as mean± SEM, n=6.

4.1.3 IPGTT
To investigate the blood glucose homeostasis in the diabetic animals, all the
experimental rat’s glucose tolerance capacity was assessed. As shown in Figure (8),
the diabetic animals showed significantly elevated glucose levels than the normal
animals prior to glucose administration (P < 0.05). After intraperitoneal glucose
administration, the blood glucose readings of the diabetic and normal rats reached the
peak within thirty-minutes however, in the normal animals, lipocalin-2 caused a
reduction in the FPG levels after 30 minutes of glucose challenge. Whereas both LCN2
and saline-treated normal control animals gradually returned to the basal levels after
120 minutes. In the diabetic group, lipocalin-2 treated diabetic animals exhibited
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improvements in response to the glucose challenge when compared to normal-saline
treated diabetic animals and lipocalin-2 caused a significant reduction in glucose levels
after 60 minutes.

Figure 8. Effects of lipocalin-2 on IPGTT after 2 weeks of treatment of normal and
diabetic animals. Note that the diabetic animals had significant higher glucose levels
when compared with the normal animals prior to glucose administration and the
glucose levels of the diabetic animals treated with LCN2 were significantly lower at
60 min after glucose administration compared to DMUT. Values represented as
mean± SEM, n=6

4.2 Insulin Release
Figure 9 shows the effect of LCN2 in stimulating insulin release from rat
insulinoma cell line.
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Figure 9: The effect of different concentrations of LCN2 in insulin secretion in INS-1
rat insulinoma cell line. Values represented as mean ± SEM, n=6 Figure (9) shows
the results of the in vitro insulin secreting properties of LCN2 in cell culture in two
different concentrations of glucose at 2.5 mM and 15 mM. Different LCN2
concentrations have been utilized in order to determine a dose-response curve for
LCN2-induced insulin secretion effects. LCN2 at 10-8 M and 10-12 M stimulated the
highest secretion of insulin in the lower glucose concentration while 10-10 M showed
less secretion. However, with the higher glucose concentration no significant effect
on insulin secretion with LCN2 was detected.

4.3 Immunohistochemical Localization of LCN2
4.3.1 Co-localization Analysis of LCN2 with Insulin in Pancreas
Double-labeling immunofluorescence technique were used to investigate
whether LCN2 co-localizes with insulin in islets of Langerhans of normal and diabetic
Wistar rats. This study demonstrates that LCN2 co-localized with insulin in the
pancreatic islets of Langerhans as shown in Figure 10.
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Figure 10: Co-localization of LCN2 with insulin in pancreatic islet cells of normal
and diabetic rats. (a) Insulin positive cells are shown by green fluorescence while
LCN2-positive cells are shown in red. The yellow color demonstrates cells that
express both LCN2 and insulin. (b) and (c) Morphometric analysis. Note that LCN2
positive cells contain both LCN2 and insulin. The micrographs are representative of
6 such animals. Scale bar = 25 µm.

4.3.2 Co-localization Analysis of LCN2 with Glucagon in Pancreas
In order to investigate whether LCN2 and glucagon are expressed in the same
cell, double labeling immunofluorescence was utilized using antibodies against LCN2
and glucagon. Glucagon was in the peripheral region of the pancreatic islets while
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LCN2 was seen in cells that dominate the middle part of the pancreatic islets of
Langerhans.

Figure 11: Co-localization of LCN2 with glucagon in pancreatic islet cells of normal
and diabetic rats. In (a) Glucagon positive cells are shown by green fluorescence
while LCN2-positive cells are shown in red. The yellow color demonstrates cells that
express both LCN2 and glucagon. (b) and (c) represents the morphometric analysis.
The micrographs are representative of 6 such animals. Scale bar = 25 µm.

4.4 Electron Microscopy
In Figures 12 and 13, show that insulin and LCN2 co-localized in the pancreatic
beta-cells. 15 nm rabbit anti-insulin and 10nm mouse anti-LCN2 gold particles
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conjugated IgG, were detected to co-exist in granules of pancreatic beta-cells. The
number of insulin secretory granules in normal animals was higher compared to
diabetic animals. Furthermore, less co-localization is seen in diabetic animals due to
derangements in granules structure and numbers as seen in Figure (13).

Figure 12: Electron micrograph showing (a) β-cell of normal rat treated with saline
with intact secretory granules and (b) β-cell of normal rat treated with LCN2 Circled
areas show the co-localization between insulin (15 nm) and LCN2 (10 nm). The
electron micrographs are typical for 6 different animals in each group. (43 k)
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Figure 13: Electron micrograph showing (a) β-cell of diabetic rat treated with saline
with deformed secretory granules and (b) β-cell of diabetic rat treated with LCN2
Circled areas show the co-localization between insulin (15 nm) and LCN2 (10 nm)
within the same granule. The electron micrographs are typical for 6 different animals
in each group. (43 k)

4.5 Markers of Oxidative Stress
The antioxidant activity of lipocalin-2 has been tested in the serum and the
pancreas tissue using colorimetric analysis and immunofluorescence analysis
respectively. Superoxide dismutase (SOD) and Glutathione reductase (GSH-red)
levels were markedly decreased in serum after the induction of DM. As shown in

59
Figure (14), (15), (16) and (17) significant decline of antioxidant enzymes activities
was observed in the STZ-induced diabetic animals. However, significant increase in
the antioxidant enzymes SOD and GSH-reductase were found in serum of the LCN2
treated STZ-induced diabetic animals when compared to the diabetic control. showing
improved ability of scavenging ROS. Moreover, all of the three target the enzyme’s
activities in the LCN2 treated diabetic animals showed almost normal levels and the
LCN2-treated control animals showed higher GSH-reductase and SOD activity than
the saline treated control animals.

Figure 14: Effects of LCN2 on SOD and GSH reductase in serum. Values
represented as mean ± SEM, n=6. Note the significant reduction in SOD and GSHreductase levels after the induction of DM. LCN2 caused a significant increase in
SOD and GSH reductase levels in serum.
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Figure 15: Effects of LCN2 on GSH reductase in pancreas of normal and diabetic
rats. Note the significant reduction in GSH reductase levels after the induction of
DM. LCN2 caused a significant increase in GSH reductase levels in the pancreas.
The micrographs are representative of 6 such animals. Values represented as mean ±
SEM. Scale bar = 25 µm.
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Figure 16: Effects of LCN2 on SOD in pancreas of normal and diabetic rats. Note the
significant reduction in SOD levels after the induction of DM. LCN2 caused a
significant increase in SOD levels in the pancreas. The micrographs are
representative of 6 such animals. Values represented as mean ± SEM. Scale bar = 25
µm.
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Figure 17: Effects of LCN2 on catalase in pancreas of normal and diabetic rats. Note
the significant reduction in catalase levels after the induction of DM. LCN2 caused a
significant increase in catalase levels in the pancreas. The micrographs are
representative of 6 such animals. Values represented as mean ± SEM. Scale bar = 25
µm.

4.6 Effects of LCN2 on Biochemical Parameters
4.6.1 Liver Function Test
Figure 18: shows a significant increase in AST and ALT levels in diabetic
control group compared to LCN2 treated and normal animals. Normal saline-animals
in addition, showed higher levels in both AST and ALT when compared to LCN2-
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treated controls, whereas there AST levels were also higher than the LCN2 received
diabetic group.

Figure 18: LCN2 effect on AST and ALT. Values represented as mean± SEM, n=6.
Note the significant elevation in AST and ALT levels in diabetic animals and the
significant effect of LCN2 in reducing both enzymes levels in the diabetic animals.
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Figure 19: shows a significant increase in ALP and Bilirubin levels in diabetic
control group compared to LCN2 treated and normal animals. In addition, ALB and
total protein were significantly down regulated in diabetic control animals when
compared to the normal controls, and an improvement in ALB and total protein
levels were detected in LCN2 treated diabetic animals.

4.6.2 Kidney Function Test
Figure (20) shows kidney function test parameters of urea, blood urea nitrogen
(BUN) and creatinine. A significant increase in urea and blood urea nitrogen levels in
diabetic control group compared to normal animals were found. LCN2 treatment
resulted in a reduction in both levels of urea and blood urea nitrogen. However, no
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significant difference was seen in creatinine levels between normal and diabetic
animals with or without the treatment.

Figure 20. Effects of LCN2 on urea, BUN and creatinine. Values represented as
mean ± SEM, n=6. Note the significant elevation in urea and BUN levels after the
induction of DM and the LCN2-induced decrease in both molecules. On the other
hand there is no noticeable difference in the levels of creatinine in all of the
experimental animals with or without the treatment.

4.6.3 Lipid Profile
Strategies for the prevention of dyslipidemia are essential for the management
and treatment of DM. in general, dyslipidemia is marked with increased TC, TG, LDLC levels and reduced HDL-C level in serum (Dixit & Kar, 2010). Lipid profile for all
the experimental groups is shown in Figure 21 The result shows that LCN2 caused a
significant reduction in triglycerides, LDL and total cholesterol levels in both normal
and diabetic treated groups compared to saline-treated littermates. Hepatic lipase was
upregulated after the induction of DM, however, it was decreased with LCN2
treatment. High-density lipoprotein levels decreased after the induction of DM and
were improved to normal levels after the treatment with LCN2.
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Figure 21: Effects of LCN2 on LDL, TG, TC, HDL and LIPC Values represented as
mean ± SEM, n=6. Note the significant reduction in LDL, TG, and TC and the
decrease in HDL and LIPC levels after the treatment by LCN2.
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4.7 Peptide Hormones Analysis
Figure (23) shows the levels of insulin in all groups. A significant reduction in
the levels of insulin was seen in diabetic animals compared to the normal control.
LCN2 caused a significant increase in the insulin levels in diabetic animals while it
had no effect in non-diabetic animals. LCN2 also caused a significant increase in the
levels of Amylin in diabetic treated group when compared to the diabetic control
animals. Figure (22), shows the effects of LCN2 treatment on GIP and GLP-1. LCN2
treatment caused a significant elevation in GIP levels in both normal and diabetic
group. On the other hand, diabetes mellitus induction caused a significant upregulation
in GLP-1 levels, which in turn was decreased after LCN2 treatment in diabetic
animals. LCN2 effects on leptin levels have been shown in Figure (25) were the
induction of DM caused marked reduction in leptin levels however, slight
improvement in leptin levels with LCN2 treatment was detected in the diabetic
animals.
Furthermore, the data shows that there was a significant reduction in C-peptide
in diabetic control group compared to normal control animals. LCN2 treatment
significantly elevated the levels of C-peptide in diabetic animals. Figure (26) shows
the effect of LCN2 on IL-6 and MCP1. DM induction caused a significant increase in
the levels of IL-6 and MCP1 and the treatment with LCN2 resulted in a significant
decrease in both levels of IL-6 and MCP1.
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Figure 22: Effects of LCN2 on GIP and GLP-1 Values represented as mean ± SEM,
n=6. Note that LCN2 significantly increased the levels of GIP in diabetic and normal
animals and decreased GLP-1 levels in diabetic animals.

Figure 23: Effects of LCN2 on Amylin and Insulin Values represented as mean ±
SEM, n=6. Note that LCN2 caused a significant increase in the levels of Amylin and
insulin in the diabetic treated group when compared to the diabetic control group.

Figure 24: Effects of LCN2 on C-peptide. Values represented as mean ± SEM, n=6.
Note that levels of c-peptide were decreased after induction of DM and LCN2 caused
a significant increase in its levels when compared with the untreated diabetic
animals.
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Figure 25: Effects of LCN2 on Leptin Values represented as mean ± SEM, n=6. Note
that LCN2 improved leptin levels in diabetic animals compared to diabetic control.

Figure 26: Effects of LCN2 on IL-6 and MCP-1 Values represented as mean ± SEM,
n= 6. Note that LCN2 significantly decreased both levels of IL-6 and MCP-1 when
compared with the diabetic control animals.

4.8 Insulin Signaling Pathway
PI3k/Akt pathway provides a survival signal that preserve cells from cell death
due to various stress stimuli, different important molecules downstream the insulin
signaling pathways including p-Akt at Ser473 and total Akt were examined to
determine whether the PI3K/Akt signal network was affected by LCN2 treatment in
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STZ induced diabetic rats. As shown in Figure 27, there is a decrease in
phosphorylation of Akt at Ser473 amino acid in the STZ-induced diabetic animals with
almost no change in total Akt protein expression in the three examined tissues,
however treatment with LCN2 enhanced the phosphorylation of Akt at Ser 473.

Figure 27: Effect of LCN2 on downstream targets of PI3K/Akt pathway in pancreas,
liver and gastrocnemius muscle of LCN2-STZ treated diabetic rats. Animals were
starved for 12 h and treated with or without STZ (60 mg/kg) body weight followed
by stimulation with 8 µg/Kg of LCN2 for 5 consecutive days/week for two weeks.
Total cell lysates were prepared and 50 μg proteins ran on SDS-PAGE followed by
western blot analysis and reactive bands were detected using ECL plus substrate.
Equal loading of protein was confirmed by probing the house keeping gene antibody
GAPDH on the same western blot membrane.
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Chapter 5: Discussion
5.1 Metabolic Parameters
5.1.1 Body Weight
All animals were maintained under similar conditions with access to water and
food for the full duration of the study. The presented results show that untreated
diabetic rats suffered from significant weight loss when compared with age-matched
normal controls. STZ-induced diabetic rats treated with LCN2 showed significant
increase in body weight and were able to maintain their normal body weight in
comparison with saline-treated diabetic group. Although LCN2 is shown to inhibit
food intake and acts as satiety signal via crossing the blood brain barrier and activating
MC4R appetite suppressing pathway (Huang et al., 2012; Petropoulou et al., 2020).
No significant weight change in the body weight of the non-diabetic LCN2 treated
group were found in comparison with the saline treated normal group. Moreover,
LCN2 reversed the weight loss associated with diabetic induction by STZ.
5.1.2 Glucose Levels
In normal animals treated with LCN2 and untreated similar fasting plasma
glucose levels were found. on the other hand, the diabetic groups showed significantly
higher glucose levels and treatment with LCN2 was not able to significantly decrease
the plasma glucose levels. although LCN2 has been reported to improve glucose
metabolism via inducing insulin secretion by various studies (Huang et al., 2012). It is
important to note that the dosage used in this study and the treatment period are
considered to be small compared to those studies. As well as the animal models and
strains could also be another factor influencing the result.
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5.1.3 Intraperitoneal Glucose Tolerance Test (IPGTT)
Plasma glucose levels before glucose administration were markedly higher in
the diabetic group compared to control group. This study demonstrated that saline
treatment was not able to reverse the sudden increase in plasma glucose levels after 30
minutes of the glucose load in control animals, however, lipocalin-2 treatment caused
a reduction in plasma glucose levels after 30 minutes of glucose administration. On
the other hand, all the diabetic groups had similar glucose readings after 30, 90 and
120 minutes of the glucose load. However, lipocalin-2 treated group showed a
significant decrease in glucose level after 60 minutes of the glucose administration.
5.2 Effects of LCN2 on Insulin Secretion In Vitro
The data show that LCN2 has a profound secretagogue effect on insulin
secretion at a dose of 10-8 M and 10-12 M in the established cell culture. LCN2, at a
dose of 10-8 M and 10-12 M resulted in a significant elevation in the levels of insulin
compared to control in the presence of 2.5 mM glucose. In the higher concentration of
glucose (15 mM), the same dose of LCN2 did not result in a significant elevation in
the insulin levels, however 10-10 M dose decreased the levels of insulin in both the
lower (2.5 mM) and the higher (15 mM) concentration of glucose.
5.3 Immunohistochemical Localization of LCN2
The number of islet cells containing LCN2 was significantly lower in the
pancreatic islet of diabetic rats when compared to normal rats. Double-labeling
immunofluorescence technique were used to investigate whether LCN2 co-localizes
with insulin in islets of Langerhans of normal and diabetic Wistar rats. This study
demonstrates that LCN2 co-localized with insulin. The percentage distribution of
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LCN2 and insulin-positive cells was close in both normal and diabetic rats, indicating
high degree of co-localization. The number of LCN2 and insulin expressing cells
declined significantly in STZ-induced diabetic rats in comparison to normal rats. The
pattern of distribution of insulin and LCN2 has been altered after DM onset.
In order to determine whether LCN2 and glucagon are found in the same cell,
double labeling immunofluorescence was utilized using antibodies against LCN2 and
glucagon. Glucagon was in the peripheral region of the pancreatic islets while LCN2
was seen in cells that dominate the middle part of the pancreatic islets of Langerhans.
There was no evidence of co-localization of LCN2 with glucagon in pancreatic islet
alpha cells in the normal rats. However, the pattern of distribution of glucagon
containing cells changed from peripheral dominant cells to center located islet cells in
diabetic rats. The number of glucagon expressing cells elevated in the islets of diabetic
rats and some degree of co-localization were found.
5.4 Distribution of Lipocalin-2 (LCN2) in Cytoplasmic Organelles of Islet Cells
EM
Since LCN2 was found to co-localize with insulin using double-labeling
immunofluorescence. Immunoelectron microscopy was conducted to determine the
intracellular localization of LCN2 in pancreatic islet cells and to further confirm what
was found at the light microscopy level. Multiple sizes of gold particles conjugated to
IgG were assessed to study the level of co-localization of LCN2 and insulin in the
cytoplasmic organelles of the beta cells. ultrathin sections processed for
immunoelectron staining showed that pancreatic beta cells definitely contain LCN2.
Gold particles conjugated IgG (10 nm) against LCN2 were observed on the secretory
granules of islet beta cells accompanied by anti-insulin antibodies conjugated to 15 nm
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gold particles. The number of 15 nm gold particles against insulin and the 10 nm gold
particles conjugated to LCN2 antibody markedly decreased after the onset of DM.
Although several researches have shown the pattern of LCN2 expression, this
is the first time to use electron microscope to localize LCN2 in the insulin-producing
beta-cells. Furthermore, the findings also demonstrate the pronounced cellular
organelle deformation and the morphological changes in the β-cells of the diabetic
animals, nuclear envelope destruction and nucleus shrinkage, enlargement of the
endoplasmic reticulum and the mitochondria and diminished secretory granules. These
structural deformities are responsible for the functional disorders in beta-cells which
mainly affect the expression and release of insulin. Moreover, the EM investigation
confirmed the immunofluorescence findings that showed the co-localization of insulin
and LCN2 in pancreatic β-cells in both normal and diabetic animals. This colocalization can explain a possible modulatory role of LCN2 in insulin-producing βcells (Huang et al., 2012).
5.5 Effects of LCN2 on Antioxidant Enzymes Activities in Serum
Oxidative stress is a common hallmark of both T1DM and T2DM; increased
biomarkers of oxidative stress are found in blood, urine and tissues including pancreas
of diabetic patients (Wang & Wang, 2017). In chronic hyperglycemia state, due to
several biochemical pathways such as nonenzymatic glycation of proteins, lipid
peroxidation and DNA oxidation increased autooxidation and generation of free
radicals is observed (Singh et al., 2005). The elevation in the reactive oxygen species
and the decline in the antioxidant defense mechanisms results in cellular damage and
the pathogenesis of vascular complications (Meenatchi et al., 2017). The common antioxidant enzymes in mammals superoxide dismutase, glutathione reductase and
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catalase have a key roles in reducing and alleviating the oxidative stress in vivo (H.
Zhao et al., 2016). Decrease in the antioxidants pool has been commonly observed in
the diabetic rats (Ananthan et al., 2004). Therefore, increased antioxidant enzymes
activities are the hallmark of anti-hyperglycemia. The antioxidant function of
lipocalin-2 have been previously studied in different stress conditions (Roudkenar et
al., 2007; Roudkenar et al., 2011; Yamada et al., 2016). And it has been shown to exert
a cytoprotective effect against oxidative stress (Roudkenar et al., 2008; Halabian et al.,
2013; Roudkenar et al., 2009). This result supports and extends the previous
knowledge of the role of LCN2 in protecting against oxidative stress by increasing the
antioxidant pool. As shown in Figure 14, significant decline of antioxidant enzymes
activities was observed in the STZ-induced diabetic animals. However, significant
increase in the antioxidant enzymes SOD and GSH-reductase were found in serum and
the pancreas tissue of the LCN2 treated STZ-induced diabetic animals when compared
to the diabetic control showing improved ability of scavenging ROS. Moreover, all of
the target enzyme’s activities in the LCN2 treated diabetic animals showed almost
normal levels and the LCN2-treated control animals showed higher SOD and GSHreductase activity than the saline treated control animals. The results suggests that
LCN2 significantly reduces and alleviate oxidative stress induced by the
hyperglycemia.
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5.6 Effect of LCN2 on Biochemical Parameters
5.6.1 Liver and Kidney Function
In this study, significant increase in aspartate aminotransferase (AST) and
alanine amino transferase (ALT) were observed post DM onset. Treatment with LCN2
lead to a significant reduction in AST and ALT in both diabetic and control animals.
This decrease in AST and ALT levels suggests a protective effect of LCN2 on the liver
function in DM. AST and ALT are liver enzymes that their levels are used as an
indicator for liver function. AST is present in the cytoplasm and mitochondria of
multiple body organs other than the liver including the heart, kidney, muscle, and
RBCs. Liver damage results in the release of AST into the bloodstream and the diabetic
animal model used in this study is characterized by upregulation in liver enzymes. Inaddition lipid peroxidation and oxidative stress are also marked by an increase in AST
which why the antioxidative stress role of LCN2 was further assessed in this study. In
the liver, the precise role of LCN2 administration has not been investigated yet,
however LCN2−/− mice were used in multiple studies to investigate the functional roles
of endogenous LCN2 in multiple experimental liver injury models. In one study, the
challenge with acute toxic chemicals or the establishment of mechanical induced
cholestasis, had a significant liver damage in LCN2−/− mice as evidenced by elevated
liver enzymes, AST and ALT post CCl4, ConA and LPS application. This suggests
that rapid LCN2 induction after direct toxic insult have a protective effect on hepatic
cells (Borkham-Kamphorst et al., 2013).
Alkaline phosphatase (ALP) is an enzyme found to be primarily expressed by
liver and bone, it has been shown to be increased in diabetes patients in comparison
with non-diabetic controls. This result comes in line with another study by (Chen et
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al., 2017) were they showed that Plasma ALP is an independent risk factor for the
incident of diabetes after adjusting other liver-related factors. And in this study, STZ
administration caused a significant increase in plasma ALP levels. However, treatment
with LCN2 caused a marked reduction in ALP levels.
Elevation in bilirubin levels is a marker for severe liver injury which is seen in
diabetic state (Zeng & Liu, 2019). The result further proved this observation, as
significant increase in bilirubin levels were found after the induction of DM, however,
treatment with LCN2 caused marked reduction in bilirubin levels.
In the body, serum albumin makes up major portion of the circulating proteins.
It is well known that in diabetes state, the total protein level decreases due to protein
breakdown as a source for energy. The results showed a significant decrease in
albumin levels after the induction of diabetes. However, treatment with LCN2
improved serum albumin levels.
In this study, the kidney function were assessed through measuring creatinine,
urea and blood urea nitrogen levels in the serum. DM induction resulted in significant
increase in the levels of both urea and blood urea nitrogen in serum. LCN2 was able
to reduce both molecules’ levels in diabetic and normal LCN2 treated animals.
However, creatinine had a minor elevation to no change after DM induction. In
literature, different research groups have investigated the role of LCN2, and kidney
injury and they have all agreed that LCN2 is a good predictor of acute kidney injury
and biomarker for chronic kidney diseases (Tang et al., 2010) since the levels of
endogenous LCN2 were higher in patients suffering from kidney disease.
Decreased total protein levels could indicate liver and/or kidney disorders
while elevated protein levels than normal are suggestive of dehydration or cancer. As
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the aim was to prove the protective role of LCN2 in diabetes mellitus, the increase and
improvement of total protein levels by LCN2 suggests the capability of the peptide in
reversing diabetic induced liver or kidney damage, in addition to reversing protein
breakdown as reported for DM in several studies. It has been reported that protein is
catabolized in severe diabetic conditions where cells are deprived of glucose (Charlton
& Nair, 1998).
5.6.2 Lipid Profile
This study showed that LCN2 significantly reduced TG levels in both diabetic
and non-diabetic animals. Moreover, there was a decline in HDL levels after the
induction of DM however, an improvement in HDL level was observed after LCN2
treatment. Significant decrease was detected in LDL-C levels with the treatment of
LCN2. No food and water restrictions were implied on all the experimental animal
groups showing that food uptake had no effect on serum TG levels. LCN2 ability to
reverse hypertriglyceridemia and its critical role in lipid metabolism has been
investigated earlier. LCN2 deficiency in mice has been shown to potentiates HFDinduced obesity, dyslipidemia, fatty liver, glucose intolerance, and insulin insensitivity
(Guo et al., 2010; Asimakopoulou et al., 2014).
5.7 Effects of LCN2 Treatment on Peptide Hormones of Normal and Diabetic
Animals
In the study, the effects of LCN2 on various other peptides that play a critical
role in metabolism and metabolic diseases such as diabetes and obesity have been
studied. Glucose balance can be maintained directly via regulating glucose synthesis
and storage or indirectly by regulating peptide hormones that could influence glucose
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levels like insulin and glucagon, based on this the effect of LCN2 treatment on insulin
hormone were investigated.
The pancreas plays a key role in body metabolism by synthesizing and
secreting multiple peptide hormones like insulin, glucagon and amylin. The results
showed that STZ administration caused a marked decrease in insulin levels in diabetic
animals compared to normal animals. Treatment of normal animals with LCN2 had no
effect in insulin levels when compared to saline-treated animals, however, treatment
with LCN2 caused a significant increase in insulin levels in diabetic treated animals in
comparison with the saline-treated animals. This upregulation in serum insulin levels
was detected only in the diabetic group which mean that enhancement of insulin
secretion could be glucose-dependent as this was not found in normal animals. This
result is consistent with those of (Mosialou et al., 2020) which was conducted to
investigate whether LCN2 is need it for β-cell adaptation to higher metabolic load via
placing murine on HFD. LCN2 stimulated and increased the secretion of insulin
approximately two folds higher in the WT mice in comparison to the Lcn2-/- which
was unable to elevate insulin levels to meet the elevated requirement of the metabolic
demand. This insulinotropic activity of LCN2 can be by stimulating β-cell
proliferation and mass or by upregulating insulin gene expression. The actual
molecular mechanism remains unknown. To verify these findings, C-peptide levels
were measured as well. C-peptide levels can offer a measure of pancreatic cell activity
that is preferable to insulin levels (Bell & Ovalle, 2000;Bulboacă et al., 2019) and
values showed similar trend to the serum insulin levels, LCN2 caused a marked
elevation in C-peptide in diabetic and normal animals. The significant improvement
of C-peptide shows that beta-cell function can be partially preserved by LCN2
treatment. This can constitute a valuable strategy in diabetes treatment.
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Amylin, another hormone synthesized and secreted by the pancreas and has a
function in glucose homeostasis through assisting insulin action in addition to its
function as a satiety agent (Ping Caoa, Peter Mareka, Harris Noora, Vadim Patsalob,
Ling-Hsien Tua, Hui Wanga, Andisheh Abedinic, 2013). There was a downregulation
in amylin levels after STZ injection and the data shows that LCN2 resulted in
significant elevation in amylin levels in diabetic group. Amylin is co-produced with
insulin in the pancreatic β-cells, the effects of LCN2 on amylin had the same trend to
its effect on insulin. Different other peptide hormones including GIP, GLP-1 and leptin
were investigated and the findings demonstrate that LCN2 significantly elevated
serum GIP levels in diabetic and normal animals. In addition, LCN2 effects on GLP1 which also belongs to the incretins family has been studied and the result showed
that diabetes mellitus induction resulted in a marked elevation in GLP-1 levels
compared to normal animals. LCN2 treatment caused a decrease in GLP-1 levels in
diabetic animals while no change was detected in normal animals. This result may be
found opposing since GLP-1 and its agonists are used clinically in the management of
diabetes mellitus and glucose levels. Having said that, these findings can be supported
by the fact that GLP-1 resistances can develop due to hyperglycemia and genetic
alterations in diabetic risk genes TCF7L2 and WFS1 (Heni et al., 2012)
This proposed mechanism is confirmed by multiple different studies that
showed a decrease of GLP-1 (Nauck et al., 1993) stimulates efficacy in patients with
diabetes mellitus. Limited knowledge is known about the correlation between LCN2
and incretins.
Leptin was also investigated as it has an important role in energy homeostasis.
Diabetes mellitus induction resulted in a significant decrease in leptin serum
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levels.LCN2 treatment improved leptin levels in normal and diabetic animals.
Previous researches demonstrated that leptin levels elevated in normal and diabetic
animals after leptin infusion inverted hyperglycemia and dyslipidemia in STZ-induced
diabetes mellitus and high fat diet induced diabetes mellitus (Denroche et al., 2011).
As a result, the hypoglycemic effects of LCN2 may be exerted through leptin levels
improvement as the data showed in the diabetic and normal rats. Mice deficient in
LCN2 showed more weight gain when placed on high fat diet (HFD), severe insulin
resistance, and impaired thermogenesis (Guo et al., 2010). Moreover, osteoblastspecific knockout of Lcn2 in murine resulted in glucose intolerance, insulin resistance,
and pancreatic β-cell dysfunction that caused a reduction in insulin secretion post
glucose challenge (Mosialou et al., 2020).
5.8 Effects of LCN2 Treatment on Inflammatory Markers of Normal and
Diabetic Animals
Inflammation could be a cause and/or a result of diabetes mellitus and it is
responsible for many complications that rise as a result of diabetes such as
cardiovascular, renal, retinal and neuronal complications. Inflammatory markers and
mediators such as IL-6 family and other chemokines like MCP-1 are suggested to be
implicated in the pathogenesis of T1DM and T2DM (Kristiansen & Mandrup-Poulsen,
2004; Padgett et al., 2013) reported that pro inflammatory cytokines are involved in
pancreatic islet cells death by triggering apoptotic or necrotic processes. IL-6 ability
as a molecule to regulate the glucose metabolism has also been suggested by acting
directly on the pancreatic cells and other different types of cells like the skeletal muscle
cells, fat cells, hepatic cells, and neuroendocrine cells (Kristiansen & MandrupPoulsen, 2004. Whereas MCP-1, In addition to its role as a chemoattractant protein
that is secreted by inflammatory cells, it could induce cellular death by oxidative stress
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pathways (Kolattukudy & Niu, 2012). Beta cells possesses a limited ability to recover
from cytokine insult, through repairing DNA damage, and enhancing insulin secretion
in case the cytokine action is shorter than 24 hours (Scarim et al., 1997). However,
irreversible cell destruction will result after 24 hours (Scarim et al., 1997). The proinflammatory cytokines induce an early necrotic process of islet cells, and with
prolonged cytokine action that can be turned into late apoptosis (Hughes et al.,
2009). DM induced by Streptozotocin (STZ) administration is a common experimental
model to investigate diabetes mellitus-associated with inflammation stimulated by the
cytotoxic effect of STZ on pancreatic beta cells. Therefore, rapid mediation of proinflammatory cytokines is considered major contributors to decrease beta-cells
destruction, caused by inflammatory process. Due to that the possible antiinflammatory role of LCN2 was investigated in the diabetic model used. LCN2
treatment had a marked effect on IL-6 where it caused a significant reduction in the
serum levels of IL-6. Moreover, MCP-1 was significantly increased after the induction
of DM and LCN2 treatment caused a significant decrease. This highlights the antiinflammatory action of LCN2.
5.9 Insulin Signaling Pathway
It has been demonstrated that PI3K/Akt signaling pathway have a crucial role
in insulin signal transduction (Li et al., 2015). In this study, the expressions of key
proteins in glucose metabolism pathway including p-Akt (ser473) and total Akt were
studied to determine whether LCN2 treatment in STZ-induced diabetic rat had an
effect on the PI3K/Akt signaling pathway. As shown in Figure (27), the levels of total
Akt in the three different tissues across all of the groups remained unchanged however,
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the study demonstrated a noticeable increase in the Akt phosphorylation in the three
examined tissues compared to the diabetic control.
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Chapter 6: Conclusion
This research provided evidence about the co-localization of LCN2 with
insulin and glucagon in normal and diabetic pancreatic β-cells. In addition, LCN2
significantly decreased levels of AST, ALT, ALP, bilirubin, CHOL, TG, LDL and
improved the levels of total protein, ALB and HDL and decreased levels of BUN, Urea
and LIPC in diabetic animals. Moreover, the levels of insulin, c-peptide, amylin and
GIP were markedly increased while GLP-1 levels were reduced and leptin levels were
improved in diabetic animals treated with LCN2. Furthermore, LCN2 showed a
significant antioxidant activity by increasing GSH, SOD and CAT levels in pancreas
in normal and diabetic animals, as well as their levels in serum. Finally, the in vitro
observations show that at a concentration of 10-8 M and 10-12 M LCN2 caused the most
significant effect on insulin secretion from the INS-1 rat insulinoma cell line.
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Chapter 7: Limitations
Some limitations for this study can be highlighted in this section including the
model of DM used in the study, which is by STZ-induced model of DM. STZ is a toxin
that is known to be highly selective for pancreatic β-cells, however, it is unknown
whether STZ can affect other organs and biological functions or not. furthermore, the
dose and the period of the treatment used were relatively short compared to doses and
durations of treatment where LCN2 was reported to increase insulin sensitivity and
weight reducing effects in literature.
In literature, LCN2 role in metabolic syndromes and energy metabolism has
been studied in a knockout model however, this is the first time to use exogenous
LCN2 in an in vivo study of metabolic syndrome.
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Chapter 8: Advancement in the Field

Management of type 1 diabetes (T1D) is currently based entirely on insulin
replacement therapy. However, there is a requirement for better glycemic control,
lower hypoglycemia rates, weight management, and additional reduction of
cardiovascular risk in T1D patients.
The peptide therapy approaches are leading the way in pre-clinical and clinical
development for both T1D and other diseases. They are entering an exciting phase of
drug development.
At the moment peptide immunotherapy for T1D is extensively researched and
it is very promising since peptide immunotherapy offers the ability to re-establish
immune

homeostasis by

elevating

regulatory

T-cell

population

and

decreasing/deleting the pathogenic T-cell pool. This is the optimal solution for T1D
since it triggers the primary cause of the beta cell destruction and depletion and
preserve the remaining cells to protect the patient’s endogenous insulin secretion.
However, a key challenge in this approach is that by the time of diagnosis substantial
loss of beta cells has already taken place. So, in this case some patients optimal solution
will include insulin therapies with an adjunct therapy.
the study shows that peptides like Lipocalin-2 can be used as adjunctive
therapy to insulin therapies for diabetes mellitus to protect from further progression of
the disease and the onset of the various complications via optimizing metabolic
control, weight management, limiting and reducing the glycemic variability in patients
with T1D and ameliorating the signs and outcome of DM.
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